Sheraz Yaqub

• Yaqub, Sheraz; Valberg, Morten; Bjørnbeth, Bjørn Atle; Angelsen, Jon-Helge; Brudvik, Kristoffer Watten & Eilertsen, Ina [Vis alle 43 forfattere av denne artikkelen] (2026). Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial. The Lancet Gastroenterology and Hepatology. ISSN 2468-1253. doi: 10.1016/s2468-1253(26)00260-8. Fulltekst i vitenarkiv Vis sammendrag

  Background Colorectal cancer frequently metastasises to the liver. Recurrence after curative-intent treatment of colorectal cancer liver metastases is common. Aspirin has shown preventive and antitumour effects in colorectal cancer, but its role after treatment of metastatic disease is uncertain. We aimed to establish whether adjuvant aspirin improves disease-free survival after curative-intent treatment of colorectal cancer liver metastases. Methods In this phase 3, randomised, double-blind, placebo-controlled trial conducted at 14 centres in Norway, Sweden, and Denmark, patients who had undergone curative-intent treatment for colorectal cancer liver metastases were randomly assigned (1:1), stratified by study site using a centrally generated computerised sequence with variable block sizes, to aspirin 160 mg per day or matching placebo for up to 3 years or until recurrence, death, or treatment discontinuation. The primary outcome was disease-free survival in the full analysis set, comprising all patients who initiated study treatment. The trial is completed and this is the final analysis. This trial is registered with ClinicalTrials.gov, NCT03326791, and EudraCT, 2014-003601-15. Findings Between Dec 15, 2017, and Jan 27, 2022, 466 patients were randomly assigned, of whom 428 initiated study treatment and were included in the full analysis set (217 assigned aspirin and 211 assigned placebo); 272 (64%) were male, 156 (36%) were female, and the mean age was 62·2 years. 269 disease-free survival events occurred (138 in the aspirin group and 131 in the placebo group). Aspirin did not improve disease-free survival (hazard ratio [HR] for recurrence or death 1·08 [95·44% CI 0·85–1·38]; p=0·58). Median disease-free survival was 1·13 years (95·44% CI 0·92–1·44) with aspirin and 1·40 years (1·11–1·69) with placebo. Overall survival at 36 months was 76% (95% CI 69·4–82·7) with aspirin and 85% (79·5–90·8) with placebo (HR for death 1·64 [95% CI 1·01–2·65]; p=0·045). Time to recurrence did not differ between groups (adjusted cause-specific HR 1·06 [95% CI 0·83–1·35]; p=0·64). 24 serious adverse events occurred in 17 (8%) of 217 patients in the aspirin group and five serious adverse events occurred in four (2%) of 211 patients in the placebo group. Clinically relevant adverse events and serious adverse events that occurred more commonly in the aspirin group than in the placebo group were myocardial infarction (two vs 0), epistaxis (four vs 0), duodenal ulcer (two vs 0), and cerebral haemorrhage (two vs 0). There were no treatment-related deaths. Interpretation Adjuvant aspirin did not improve disease-free survival and was associated with lower overall survival and more serious adverse events. These findings do not support routine use of aspirin after curative-intent treatment of colorectal cancer liver metastases.

• Smedman, Tor Magnus; Fretland, Åsmund Avdem; Dueland, Svein; Solheim, Jon Magnus Aarstrand; Hagness, Morten & Lassen, Kristoffer [Vis alle 8 forfattere av denne artikkelen] (2026). Liver Transplantation for Unresectable Colorectal Liver Metastases: Evidence, Patient Selection, and Clinical Implementation. Cancers. 18(14). doi: 10.3390/cancers18142306. Fulltekst i vitenarkiv Vis sammendrag

  Liver transplantation (LT) has re-emerged as a potentially curative treatment for carefully selected patients with unresectable, liver-only colorectal liver metastases (CRLM). Prospective trials (SECA-I/II) demonstrated 5-year overall survival (OS) rates of 60–83% in selected patients, findings recently corroborated by the randomized TransMet trial, which showed superior 5-year OS with LT compared with chemotherapy alone. Favorable outcomes depend on rigorous patient selection integrating clinical risk stratification (Oslo Score), tumor burden assessed by metabolic tumor volume on FDG-PET-CT, and molecular profiling, while excluding high-risk features such as BRAF V600E and RAS/TP53 co-mutations. Broader implementation raises ethical challenges related to organ allocation, driving interest in alternative strategies including living-donor LT and innovative procedures such as RAPID. This narrative review summarizes evolving evidence supporting LT for CRLM, current approaches to patient selection, oncological outcomes, and practical considerations for implementing LT into contemporary HPB and transplant practice.

• Glent, John C.F.; Haugen, Joachim B.; Helgestad, Ida; Azanjac, Branislav; Yaqub, Sheraz & Aghayan, Davit [Vis alle 7 forfattere av denne artikkelen] (2026). Implementation of robot-assisted transabdominal preperitoneal inguinal hernia repair: A prospective cohort study. Scandinavian Journal of Surgery. ISSN 1457-4969. doi: 10.1177/14574969261459827. Fulltekst i vitenarkiv
• Kryeziu, Kushtrim; Klokkerud, Solveig Knoph; Totland, Max Zachrisson; Moosavi, Hossein; Reims, Henrik Mikael & Bergsland, Christian Holst [Vis alle 17 forfattere av denne artikkelen] (2026). Patient-derived organoids from metastatic colorectal cancer mirror tumor heterogeneity and predict patient survival and drug sensitivity. Cell Reports Medicine. 7(6). doi: 10.1016/j.xcrm.2026.102840. Fulltekst i vitenarkiv Vis sammendrag

  This study reports the pharmacogenomic analysis of tumor heterogeneity in a living biobank of 213 organoids derived from liver metastases of 102 patients with metastatic colorectal cancer. Successful organoid establishment reflects poorer chemosensitivity and patient survival. Molecular fidelity is confirmed in tumor-organoid pairs, and multi-modal phenotypes are defined based on organoid morphology. Cystic morphology associates with intestinal stem cell markers and greater drug sensitivity, while solid morphology is linked to markers of plasticity and aggressiveness. The potential to identify treatments less affected by tumor heterogeneity is supported by multi-lesion analyses in 65 patients. Clinical translation is illustrated in two prospective cases of pharmacogenomics-guided treatment, including successful chemotherapy rechallenge and targeted therapy resistance in cancers with low and high heterogeneity. All pharmacogenomic data are openly available as a functional oncology resource to support interpretation of ex vivo drug sensitivities into clinical “actionability.”

• Syversveen, Trygve; Hansen, Ingrid Schrøder; Brabrand, Knut; Brudvik, Kristoffer Watten; Bjørk, Ida Torunn & Østergaard, Daniel [Vis alle 12 forfattere av denne artikkelen] (2026). Intra-procedural CT control versus ultrasound only in ultrasound-guided thermal ablation of colorectal liver metastases: a single-centre cohort study. Surgical Endoscopy. ISSN 0930-2794. doi: 10.1007/s00464-026-12912-4. Fulltekst i vitenarkiv Vis sammendrag

  Background Local ablative treatment is increasingly used for small colorectal liver metastasis (CRLM). Adequate ablative margins are essential for achieving local control, yet reported rates of local tumour progression (LTP) vary widely. This study compared LTP rate after ultrasound (US)-guided ablation of CRLM performed with versus without intraoperative CT control. Methods All percutaneous US-guided ablations for CRLM performed in a single centre from 2018 to 2021 were reviewed for LTP. Procedures with intraprocedural CT (CT group), allowing immediate re-ablation for margin extension, were compared with procedures without intraprocedural CT control (OR group). Results A total of 152 procedures in 137 patients were analysed. In the CT group, 5 LTP events (8.0%) occurred after 62 procedures, affecting 5 of 111 CRLM (4.5%). In the OR group, 20 LTP events (22.2%) occurred after 90 procedures, affecting 22 of 132 CRLM (16.6%) (procedure-based and lesion-based p = 0.0035 and p = 0.0255), respectively. For CRLM ≤ 10 mm visualized with US, LTP occurred in 1/50 lesions (2%) in the CT group and 0/51 lesions (0%) in the OR group (p = 0.495). Most LTP occurred with synchronous recurrence elsewhere in the liver (CT group 3/5 [60%], OR group 16/22 [73%]). Only minor complications, Accordion grades 1–2, were observed with similar frequency (8% vs. 12% in CT group and OR group, respectively). Conclusion Intraprocedural CT control was associated with substantially lower LTP, suggesting that CT control should be considered standard when available. US-only ablation may remain appropriate for small, clearly visualized lesions.

• Hansen, Ingrid Schrøder; Aghayan, Davit; Pelanis, Egidijus; Røsok, Bård Ingvald; Brudvik, Kristoffer Watten & Yaqub, Sheraz [Vis alle 12 forfattere av denne artikkelen] (2026). Long-Term Oncological Outcomes After Laparoscopic Resection and Thermal Ablation of Colorectal Liver Metastases Within a Parenchyma-Sparing Strategy. Annals of Surgical Oncology. ISSN 1068-9265. doi: 10.1245/s10434-026-19621-1. Fulltekst i vitenarkiv Vis sammendrag

  Background Thermal ablation of colorectal liver metastases (CRLM) is traditionally reserved for patients who are not candidates for surgical resection, but it is increasingly applied as a parenchyma-sparing alternative. This study investigates long-term outcomes following laparoscopic resection and thermal ablation in a parenchyma-sparing treatment strategy. Methods Cohort study of patients with CRLM treated with laparoscopic resection or thermal ablation at Oslo University Hospital between 2007 and 2020, identified from two prospectively maintained databases. The primary endpoint was the average treatment effect on survival, estimated using inverse probability weighting to adjust for prognostic variables. Secondary endpoints included overall survival and progression-free survival. In case of recurrence of liver metastases after the study treatment, both ablation and resection were used. Results A total of 207 ablation procedures and 499 resection procedures were eligible for analysis. Five-year overall survival was 55.2% in the ablation group and 55.1% in the resection group. The estimated average treatment effect of ablation versus resection was − 0.34 months (95% confidence interval − 7.29 to 6.57; P = 0.919), indicating that treating all patients with ablation would yield an average survival of 0.34 months shorter than treating all patients with resection. Conclusions In a parenchymal-sparing paradigm, thermal ablation yields long-term survival comparable to resection for CRLM.

• Holm, Maia Blomhoff; Busund, Sondre; Rihel, Rahul; Sahakyan, Mushegh; Verbeke, Caroline Sophie & Yaqub, Sheraz [Vis alle 7 forfattere av denne artikkelen] (2026). Outcome of resectable distal cholangiocarcinoma in a single-centre Western patient cohort: comparison of the 7^thand 8^thedition of the UICC/AJCC TNM classification. Acta Oncologica. ISSN 0284-186X. 65, s. 148–155. doi: 10.2340/1651-226X.2026.44965. Fulltekst i vitenarkiv
• Schultz, Johannes Kurt; Sigurdardottir, Johanna M.; Bakstad, Linda Tøften; Thorisson, Arnar; Yaqub, Sheraz & Chabok, Abbas [Vis alle 8 forfattere av denne artikkelen] (2026). Accuracy and reliability of preoperative CT in perforated diverticulitis: Post hoc secondary analysis from the SCANDIV trial. Scandinavian Journal of Surgery. ISSN 1457-4969. doi: 10.1177/14574969261418419. Fulltekst i vitenarkiv
• Zompo, Fabio Del; Crouchet, Emilie; Ostyn, Tessa; Nehme, Zeina; Messé, Mélissa & Jühling, Frank [Vis alle 36 forfattere av denne artikkelen] (2025). Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis. Journal of Hepatology. ISSN 0168-8278. 83(6), s. 1305–1319. doi: 10.1016/j.jhep.2025.08.005. Fulltekst i vitenarkiv Vis sammendrag

  Background & Aims Primary sclerosing cholangitis (PSC) is a cholangiopathy associated with a high risk of progression to end-stage liver disease and hepatobiliary cancer. Its pathogenesis remains poorly understood, and current clinical management offers limited therapeutic options, primarily liver transplantation. Claudin-1 (CLDN1), a transmembrane protein highly expressed in liver epithelial cells, plays a critical role in cell-cell communication and signaling. We aimed to investigate the functional role of CLDN1 as both a mediator and potential therapeutic target for PSC using patient cohorts alongside murine and patient-derived intervention models. Methods CLDN1 expression patterns and associated cellular phenotypes were analyzed in liver tissues from five PSC patient cohorts using single-cell RNA sequencing, spatial transcriptomics, and multiplex proteomics. Proof-of-concept studies employing CLDN1-specific monoclonal antibodies (mAbs) and genetic loss-of-function approaches were performed in state-of-the-art mouse models of PSC and cholangiopathies. Perturbation studies in human cell-based models were conducted to explore underlying mechanisms. Results In liver tissues from patients with PSC, CLDN1 expression was markedly upregulated and correlated with disease progression. Spatial transcriptomics and proteomics revealed elevated CLDN1 expression in diseased cholangiocytes and cholestatic periportal hepatocytes, accompanied by activation of pro-inflammatory and pro-fibrotic signaling pathways. Therapeutic administration of CLDN1-specific mAbs or genetic knockout improved liver function in PSC mouse models by reducing hepatobiliary fibrosis and cholestasis. Mechanistic studies indicated that mAb treatment inhibited pro-inflammatory and pro-fibrotic signaling in cholangiocytes and hepatocytes perturbed in PSC liver tissues. Conclusions These findings demonstrate a functional role for CLDN1 in the pathogenesis of PSC and biliary fibrosis. In vivo proof-of-concept studies, combined with expression analyses in patients with PSC, support the clinical development of CLDN1-specific mAbs as a therapeutic strategy for PSC. Impact and implications Primary sclerosing cholangitis (PSC) is a chronic fibrosing cholangiopathy with limited therapeutic options. We identified the cell surface protein Claudin-1 as a key mediator and potential therapeutic target for PSC. In patients, Claudin-1 expression correlates with disease stage and clinical outcomes. Conditional liver epithelial-specific Claudin-1 knockout in mice reduced liver injury, fibrosis, and cholestasis. Monoclonal antibodies targeting Claudin-1 inhibited fibrosis, cholestasis, and the ductular reaction across advanced PSC mouse models by suppressing pro-inflammatory and fibrogenic signaling. These preclinical findings support the clinical development of Claudin-1-specific antibodies for PSC treatment and have significant implications for physicians, researchers, and drug developers in the field of biliary disease.

• Yaqub, Sheraz; Brudvik, Kristoffer Watten; Smedman, Tor Magnus; Syversveen, Trygve; Line, Pål Dag & Dueland, Svein (2025). Liver transplantation for colorectal metastases following hepatic resection. British Journal of Surgery. ISSN 0007-1323. 112(9). doi: 10.1093/bjs/znaf193. Fulltekst i vitenarkiv
• Røsok, Bård Ingvald; Ahmad, Somaya Habib; Fretland, Åsmund Avdem; Østergaard, Daniel; Edwin, Bjørn von Gohren & Brudvik, Kristoffer Watten [Vis alle 7 forfattere av denne artikkelen] (2025). Surgical resection of adrenal metastases: Single-center experience and narrative literature review with emphasis on colorectal metastases. Scandinavian Journal of Surgery. ISSN 1457-4969. 114(2), s. 142–146. doi: 10.1177/14574969251331341. Fulltekst i vitenarkiv Vis sammendrag

  Adrenal glands can host metastases from various malignancies. While surgical resection offers potential benefits in solitary- or oligometastatic cases, many patients have systemic disease unsuitable for surgery when adrenal metastases are diagnosed. Most adrenal metastases originate from malignancies in the lungs, kidneys, or liver. This review explores diagnostic and treatment strategies for adrenal metastases including data from a single center. In particular, it is shown that surgical resection of metastases from colorectal cancer to the adrenals may offer a potential survival benefit. Personalized treatment plans and further research are critical for improving outcomes for patients with adrenal metastases.

• Line, Pål Dag; Yaqub, Sheraz; Lassen, Kristoffer; Wiencke, Kristine; Khan, Ammar & Fosby, Bjarte [Vis alle 9 forfattere av denne artikkelen] (2025). A novel transplant approach for locally advanced unresectable perihilar cholangiocarcinoma: the SURE-LT concept. Annals of Surgery. ISSN 0003-4932. s. 1–9. doi: 10.1097/SLA.0000000000006892. Fulltekst i vitenarkiv
• Angelsen, Jon-Helge; Yaqub, Sheraz; Hegvik, Tor-Arne; Nymo, Linn Såve; Veen, Torhild & Dagenborg, Vegar Johansen [Vis alle 7 forfattere av denne artikkelen] (2025). Outcomes of simultaneous resection for colorectal liver metastases: A nationwide cohort study (2005–2022). Surgery Open Science. 27, s. 113–119. doi: 10.1016/j.sopen.2025.07.008. Fulltekst i vitenarkiv
• Casulli, Adriano; Abela, Bernadette; Petrone, Daniele; Šoba, Barbara; Dezsényi, Balázs & Karamon, Jacek [Vis alle 47 forfattere av denne artikkelen] (2025). Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project. The Lancet Infectious Diseases. ISSN 1473-3099. 26(1), s. e49–e61. doi: 10.1016/S1473-3099(25)00283-X. Fulltekst i vitenarkiv
• Yaqub, Sheraz; Longva, Anne Madsi; Angelsen, Jon-Helge; Brudvik, Kristoffer Watten; Carling, Johan Ulrik & Edwin, Bjørn von Gohren [Vis alle 15 forfattere av denne artikkelen] (2025). Multimodal treatment for colorectal liver metastases: A toolbox for clinicians. Scandinavian Journal of Surgery. ISSN 1457-4969. 114(2), s. 126–134. doi: 10.1177/14574969251333524. Fulltekst i vitenarkiv Vis sammendrag

  Colorectal cancer is the second most common cause of cancer-related death worldwide, and liver metastases are the leading cause of mortality in these patients. Surgical innovations combined with modern systemic chemotherapy have improved 5-year overall survival rates. This review aims to equip non-hepatobiliary surgeons with a comprehensive toolbox for the diagnosis and management of colorectal liver metastases. It covers the current landscape of diagnostic workup, including imaging modalities and biomarkers, and reviews the surgical and nonsurgical treatment options. This guide attempts to enhance multidisciplinary care for patients with colorectal liver metastases by integrating evidence-based practices with innovative strategies, which can improve outcomes and survival.

• Aune, Dagfinn; Nordsletten, Marie Wiborg; Myklebust, Tor Åge; Robsahm, Trude Eid; Skålhegg, Bjørn Steen & Mala, Tom [Vis alle 8 forfattere av denne artikkelen] (2025). Body mass index and risk of Hodgkin's lymphoma: Insights from a Norwegian cohort study. European Journal of Cancer. ISSN 0959-8049. 221. doi: 10.1016/j.ejca.2025.115400. Fulltekst i vitenarkiv Vis sammendrag

  Background Several studies have reported positive associations between higher body mass index (BMI) and risk of Hodgkin's lymphoma. However, the evidence is not entirely consistent. We investigated the association between BMI and Hodgkin's lymphoma in a large Norwegian cohort with up to 50 years follow-up. Methods The analytical dataset included 1723,692 men and women aged 16–75 years at baseline in 1963–1975. Multivariable Cox regression analyses were used to estimate hazard ratios (HRs) and 95 % confidence intervals (CIs) for the associations between BMI and Hodgkin's lymphoma incidence. Results During 56.1 million person-years of follow-up, 1608 incident Hodgkin's lymphoma cases occurred. Compared to individuals with BMI 18.5-< 25, the HRs (95 % CIs) for those with a BMI of 15-< 18.5, 25-< 30, and ≥ 30 were 0.87 (0.59–1.27), 1.05 (0.94–1.18), and 1.61 (1.35–1.91), respectively, and 1.57 (1.30–1.90) and 1.80 (1.24–2.62) for obesity grade 1 and grade 2, respectively. A positive association was also observed per 5 kg/m2 increment with a HR (95 % CI) of 1.16 (1.08–1.24) overall, 1.20 (1.09–1.31) in women, and 1.08 (0.96–1.20) in men. Positive associations were also observed between obesity vs. normal weight in early adulthood (age 16–29 years) and Hodgkin's lymphoma (HR, 95 % CIs: 1.89, 1.10–3.22, ptrend<0.0001, n = 489 cases) and between obesity and early-onset (age <50 years at diagnosis) disease (HR, 95 % CIs: 1.67, 1.01–2.78, ptrend<0.0001, n = 393 cases). Conclusion The positive associations observed between higher BMI overall and in young adulthood and Hodgkin's lymphoma and between BMI and early-onset disease emphasize the potential role of adiposity in development of this malignancy.

• Aune, Dagfinn; Nordsletten, Marie Wiborg; Myklebust, Tor Åge; Robsahm, Trude Eid; Skålhegg, Bjørn Steen & Mala, Tom [Vis alle 8 forfattere av denne artikkelen] (2025). Body mass index and risk of connective and soft tissue cancer: results from a large cohort of 1.7 million individuals in Norway. BMC Cancer. 25. doi: 10.1186/s12885-025-13637-8. Fulltekst i vitenarkiv Vis sammendrag

  Background Few studies have investigated the association between adiposity and connective and soft tissue cancer, a rare and understudied cancer entity. We investigated this association in a large cohort of more than 1.7 million individuals in Norway. Methods The study cohort included 1,723,692 men and women aged 16–75 years at baseline in 1963–1975. Data on weight and height measurements from the Norwegian Tuberculosis Screening Programme were linked to the Cancer Registry. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between body mass index (BMI) and risk of connective and soft tissue cancer, adjusting for age and sex. Results In total 1758 connective and soft tissue cancer cases were registered during 56.1 million person-years of follow-up. The HRs (95% CIs) for the BMI categories of 15-<18.5, 18.5-<25.0 (reference), 25.0-<30.0, 30.0-<35.0, ≥ 35.0 were 0.77 (0.50–1.20), 1.00 (reference), 1.15 (1.03–1.27), 1.28 (1.06–1.54), and 1.69 (1.21–2.37, ptrend<0.0001). The HR per 5 kg/m2 increment in BMI was 1.14 (1.07–1.22) overall, 1.10 (0.99–1.23) in men and 1.17 (1.08–1.27) in women. Obesity in early adulthood (age 16–29 years) showed a suggestive positive association with connective and soft tissue cancer risk with HR (95%CIs) of 1.73 (0.95–3.16), ptrend=0.09) when compared to normal weight. No clear association was observed between BMI and early-onset (age < 50 years at diagnosis) connective and soft tissue cancer. Positive associations were observed between BMI and soft tissue sarcoma, fibrosarcoma, dermatofibroma, and lipoleiomyoma, but no clear associations were observed with fibrous histiocytoma and liposarcoma. Conclusion These results suggest that higher BMI overall and in early adulthood may be associated with increased risk of connective and soft tissue cancer, but BMI seems not to influence early-onset disease. Large cohort studies with more detailed information on confounding factors and BMI trajectories over time are needed for further verification before firm conclusions can be made.

• Aune, Dagfinn; Nordsletten, Marie Wiborg; Myklebust, Tor Åge; Robsahm, Trude Eid; Skålhegg, Bjørn Steen & Mala, Tom [Vis alle 8 forfattere av denne artikkelen] (2025). Body mass index and ampulla of Vater cancer incidence and survival: a cohort study of 1.7 million Norwegians. Hepatobiliary surgery and nutrition. ISSN 2304-3881. s. 1–8. doi: 10.21037/hbsn-2024-636. Fulltekst i vitenarkiv Vis sammendrag

  Background: Although higher body mass index (BMI) has been associated with increased risk of hepatobiliary cancers in previous studies, the association with risk of ampulla of Vater cancer has rarely been reported. We therefore investigated the association between BMI and ampulla of Vater cancer incidence in a large Norwegian cohort. Methods: The analytical dataset included 1,723,692 men and women aged 16–75 years at baseline in 1963– 1975. Multivariable Cox regression analyses were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between BMI and ampulla of Vater cancer incidence and survival. Results: During 56.1 million person-years of follow-up, a total of 814 cases with ampulla of Vater cancer were identified. Compared to participants with a BMI of 18.5–<25 kg/m2, the HRs (95% CIs) of those with a BMI of 15–<18.5, 25–<30, and ≥30 kg/m2 were 0.19 (0.05–0.77), 1.02 (0.88–1.19), and 1.03 (0.80–1.32), respectively, and 1.02 (0.92–1.12) per 5 kg/m2 increment. No association was observed in men and women, when analysed separately. The HRs (95% CIs) for BMI in young adulthood were 0.39 (0.10–1.57), 1.00, 1.26 (0.80–1.99), and 3.62 (1.76–7.48, Ptrend=0.004) for a BMI of 15–<18.5, 18.5–<25.0, 25–<30, and ≥30 kg/m2, and 1.61 (1.25–2.06) per 5 kg/m2 increment (n=130), and for early-onset ampulla of Vater cancer (n=19) was 1.00, 2.10 (0.75–5.88), and 5.45 (1.16–25.70, Ptrend=0.01), and 1.91 (1.10–3.32) per 5 kg/m2 increment. Higher BMI was not clearly associated with cancer-specific survival among ampulla of Vater cancer patients (HR 1.19, 95% CI: 0.89–1.61 for BMI ≥30 vs. 18.5–<25.0 kg/m2). Conclusions: Overall, the results show no clear association between higher BMI and ampulla of Vater cancer incidence or survival. However, strong positive associations were observed between BMI in young adulthood and risk of ampulla of Vater cancer and between BMI and early-onset diagnosis. Further studies are needed to verify these findings.

• Yaqub, Sheraz; Busund, Sondre; Smedman, Tor Magnus; Syversveen, Trygve; Khan, Ammar & Solheim, Jon Magnus Aarstrand [Vis alle 11 forfattere av denne artikkelen] (2025). Liver transplantation for locally advanced non-resectable intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: early results from the TESLA trial. British Journal of Surgery. ISSN 0007-1323. 112(3). doi: 10.1093/bjs/znaf054. Fulltekst i vitenarkiv
• Saeed, Usman; Myklebust, Tor Åge; Robsahm, Trude Eid; Aune, Dagfinn; Møller, Bjørn & Skålhegg, Bjørn Steen [Vis alle 8 forfattere av denne artikkelen] (2025). Associations between body mass index and gastroesophageal cancer incidence and mortality: novel insights from a nationwide registry-based cohort study. Diseases of the esophagus. ISSN 1120-8694. 38(2). doi: 10.1093/dote/doaf018. Fulltekst i vitenarkiv Vis sammendrag

  The association between body mass index (BMI) and cancers of the esophagus and the stomach remains complex and requires further exploration. This study aimed to investigate this association, including early-onset (< 50 years) cancer and cancer related mortality. A nationwide registry-based cohort study was performed by linking data from multiple national registries in Norway. The cohort included 1,723,692 individuals, with 22,473 gastroesophageal cancer cases identified over 55,701,169 person-years of follow-up. In men, a 5 kg/m2 increase in BMI was associated with an increased risk of esophageal (HR 1.34, 95%CI 1.22–1.48) and cardia adenocarcinoma (HR 1.36, 95% CI, 1.22–1.50). This finding extended to individuals with high BMI in early life (16–29 years) for esophageal adenocarcinoma. The highest risk per 5 kg/m2 increase in BMI was observed for early-onset esophageal (HR 2.49, 95%CI 1.23–5.02) and cardia adenocarcinoma (HR 2.26, 95%CI 1.19–4.27). Among women, increased BMI was associated with a higher risk of both esophageal (HR 1.28, 95%CI 1.13–1.44) and gastric adenocarcinoma (HR 1.04, 95%CI 1.01–1.07). Women with elevated BMI in early life also demonstrated increased risk for these cancers. In both sexes, a 5 kg/m2 increase in BMI was inversely associated with squamous cell carcinoma of the esophagus. No association was observed between BMI and risk of cancer-related mortality. This study highlights an elevated risk of gastroesophageal adenocarcinomas with increasing BMI, with notable sex, age, and site-specific variations. The findings also point to a heightened risk of early-onset esophageal and cardia adenocarcinoma in men with high BMI.

• Aune, Dagfinn; Mala, Tom; Myklebust, Tor Åge; Nordsletten, Marie Wiborg; Robsahm, Trude Eid & Saeed, Usman [Vis alle 8 forfattere av denne artikkelen] (2024). The association between body mass index and vulvar and vaginal cancer incidence: findings from a large Norwegian cohort study | Cancer Causes & Control. Cancer Causes and Control. ISSN 0957-5243. 36(2), s. 191–198. doi: 10.1007/s10552-024-01930-z. Fulltekst i vitenarkiv Vis sammendrag

  There is limited evidence of potential associations between body mass index (BMI) and risk of vulvar and vaginal cancer. We explored these associations in a large cohort of Norwegian women. The analytical dataset included 889,441 women aged 16–75&nbsp;years at baseline in 1963–1975. Multivariable Cox regression analyses were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between BMI and vulvar and vaginal cancer incidence. During 30.1 million person-years of follow-up, 1748 incident vulvar and 408 incident vaginal cancer cases occurred. The HRs (95% CIs) for vulvar cancer for a BMI of 15- &lt; 18.5, 18.5- &lt; 25, 25- &lt; 30, 30- &lt; 35, ≥ 35 were 0.62 (0.38–1.01), 1.00 (reference), 1.23 (1.10–1.40), 1.43 (1.23–1.66) and 1.72 (1.35–2.20, ptrend &lt; 0.001), and per 5&nbsp;kg/m2 increment was 1.20 (1.13–1.26). The corresponding HRs (95% CIs) for vaginal cancer were 1.05 (0.52–2.15), 1.00, 0.89 (0.71–1.12), 0.95 (0.68–1.34), and 2.01 (1.29–3.13, ptrend &lt; 0.001), respectively, and per 5&nbsp;kg/m2 was 1.11 (0.99–1.25). The HR (95% CI) per 5&nbsp;kg/m2 increase in BMI at ages 16–29 was 1.28 (1.07–1.54, n = 250 cases) for vulvar and 1.53 (1.11–2.11, n = 66 cases) for vaginal cancers. The HR (95% CI) per 5&nbsp;kg/m2 for early-onset (&lt; 50&nbsp;years age at diagnosis) vulvar cancer was 0.92 (0.66–1.28, n = 87 cases) and 1.70 (1.05–2.76, n = 21 cases) for vaginal cancer. These results further support the associations between higher BMI and increased risk of vulvar and vaginal cancers, with suggestive stronger associations between BMI in early adulthood for both cancers and for early-onset vaginal cancer. Further studies are needed to elucidate these findings and investigate the underlying mechanisms.

• Carling, Johan Ulrik; Berger, Sigurd; Gjønnæss, Eyvind; Røsok, Bård Ingvald; Yakub, Sheraz & Lassen, Kristoffer [Vis alle 8 forfattere av denne artikkelen] (2024). Transfemoral hepatic vein access in double vein embolization – initial experience and feasibility. CVIR Endovascular. 7(1). doi: 10.1186/s42155-024-00478-y. Fulltekst i vitenarkiv Vis sammendrag

  Background Hepatic vein embolization in double vein embolization (DVE) can be performed with transhepatic, transjugular or transfemoral access. This study evaluates the feasibility and technical success of using a transfemoral access for the hepatic vein embolization in patients undergoing preoperative to induce hypertrophy of the future liver remnant (FLR).<p> <p>Material and methods Retrospective analysis of single center cohort including 17 consecutive patients. The baseline standardized FLR was 18.2% (range 14.7–24.9). Portal vein embolization was performed with vascular plugs and glue through an ipsilateral transhepatic access. Hepatic vein embolization was performed using vascular plugs. Access for the hepatic vein was either transhepatic, transjugular or transfemoral. Technical success, number of hepatic veins embolized and complications were registered. In addition, volumetric data including degree of hypertrophy (DH) and kinetic growth rate (KGR), and resection data were registered. R: Seven of the 17 patients had transfemoral hepatic vein embolization, with 100% technical success. No severe complications were registered. In the whole cohort, the median number of hepatic veins embolized was 2 (1–6). DH was 8.6% (3.0–19.4) and KGR was 3.6%/week (1.4–7.4), without significant differences between the patients having transfemoral versus transhepatic /transjugular access (p=0.48 and 0.54 respectively). Time from DVE to surgery was median 4.8 weeks (2.6–33.9) for the whole cohort, with one patient declining surgery, two having explorative laparotomy and one patient having change of surgical strategy due to insufficient growth. <p>Conclusion Transfemoral access is a feasible option with a high degree of technical success for hepatic vein embolization in patients with small future liver remnants needing DVE.

• Braadland, Peder Rustøen; Farnes, Ingvild; Kure, Elin Wenche Hegland; Yaqub, Sheraz; McCann, Adrian & Ueland, Per Magne [Vis alle 8 forfattere av denne artikkelen] (2024). Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer. Frontiers in Oncology. 14. doi: 10.3389/fonc.2024.1488749. Fulltekst i vitenarkiv Vis sammendrag

  Background/Aims: It was recently reported that a higher concentration of the bacterially produced metabolite indole 3-acetate (3-IAA) in blood was linked to a better response to chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Here, we aimed to extend these observations to patients diagnosed with non-metastatic PDAC. Method: We measured circulating 3-IAA in samples from a prospective population-based cohort of 124 patients with borderline resectable or locally advanced PDAC, collected before initiating neoadjuvant chemotherapy. The majority (61%) of the patients were treated with FOLFIRINOX. We used univariable and multivariable Cox proportional hazards regression to estimate the association between pre-treatment 3-IAA and overall survival. Results: The median serum 3-IAA concentration before chemotherapy was 290 (interquartile range 203–417) ng/mL. The unadjusted hazard ratio (HR) for pre-treatment log2(3-IAA) was 0.93, 95% confidence interval (CI) [0.74–1.16], p=0.52. When adjusting for age, ECOG, CA19-9 and tumor classification, the HR for log2(3-IAA) was 0.87, 95% CI [0.68–1.12], p=0.28. Conclusion: Our findings suggest that the potentiating effect of 3-IAA observed in metastatic PDAC undergoing chemotherapy may not translate to borderline resectable or locally advanced PDAC. We recommend additional clinical validation of 3-IAA’s predictive value in different categories of PDAC before implementation attempts in human studies are initiated.

• Yakub, Sheraz; Røsok, Bård Ingvald; Gladhaug, Ivar Prydz & Labori, Knut Jørgen (2024). Pancreatic duct occlusion with polychloroprene-based glue for the management of postoperative pancreatic fistula after pancreatoduodenectomy—an outdated approach? Frontiers in Surgery. 11. doi: 10.3389/fsurg.2024.1386708. Fulltekst i vitenarkiv Vis sammendrag

  Background: Managing postoperative pancreatic fistula (POPF) presents a formidable challenge after pancreatoduodenectomy. Some centers consider pancreatic duct occlusion (PDO) in reoperations following pancreatoduodenectomy as a pancreas-preserving procedure, aiming to control a severe POPF. The aim of the current study was to evaluate the short- and long-term outcomes of employing PDO for the management of the pancreatic stump during relaparotomy for POPF subsequent to pancreatoduodenectomy. Methods: Retrospective review of consecutive patients at Oslo University Hospital undergoing pancreatoduodenectomy and PDO during relaparotomy. Pancreatic stump management during relaparotomy consisted of occlusion of the main pancreatic duct with polychloroprene Faxan-Latex, after resecting the dehiscent jejunal loop previously constituting the pancreaticojejunostomy. Results: Between July 2005 and September 2015, 826 pancreatoduodenectomies were performed. Overall reoperation rate was 13.2% (n = 109). POPF grade B/C developed in 113 (13.7%) patients. PDO during relaparotomy was performed in 17 (2.1%) patients, whereas completion pancreatectomy was performed in 22 (2.7%) patients. Thirteen (76%) of the 17 patients had a persistent POPF after PDO, and the time from PDO until removal of the last abdominal drain was median 35 days. Of the PDO patients, 13 (76%) patients required further drainage procedures (n = 12) or an additional reoperation (n = 1). In-hospital mortality occurred in one patient (5.9%). Five (29%) patients developed new-onset diabetes mellitus, and 16 (94%) patients acquired exocrine pancreatic insufficiency. Conclusions: PDO is a safe and feasible approach for managing severe POPF during reoperation following pancreatoduodenectomy. A significant proportion of patients experience persistent POPF post-procedure, necessitating supplementary drainage interventions. The findings suggest that it is advisable to explore alternative pancreas-preserving methods before opting for PDO in the management of POPF subsequent to pancreatoduodenectomy.

• Labori, Knut Jørgen; Bratlie, Svein Olav; Andersson, Bodil; Angelsen, Jon-Helge; Biörserud, Christina & Björnsson, Bergthor [Vis alle 35 forfattere av denne artikkelen] (2024). Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial. The Lancet Gastroenterology and Hepatology. ISSN 2468-1253. 9(3), s. 205–217. doi: 10.1016/S2468-1253(23)00405-3. Fulltekst i vitenarkiv Vis sammendrag

  Background In patients undergoing resection for pancreatic cancer, adjuvant modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) improves overall survival compared with alternative chemotherapy regimens. We aimed to compare the efficacy and safety of neoadjuvant FOLFIRINOX with the standard strategy of upfront surgery in patients with resectable pancreatic ductal adenocarcinoma. Methods NORPACT-1 was a multicentre, randomised, phase 2 trial done in 12 hospitals in Denmark, Finland, Norway, and Sweden. Eligible patients were aged 18 years or older, with a WHO performance status of 0 or 1, and had a resectable tumour of the pancreatic head radiologically strongly suspected to be pancreatic adenocarcinoma. Participants were randomly assigned (3:2 before October, 2018, and 1:1 after) to the neoadjuvant FOLFIRINOX group or upfront surgery group. Patients in the neoadjuvant FOLFIRINOX group received four neoadjuvant cycles of FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, and fluorouracil 400 mg/m2 bolus then 2400 mg/m2 over 46 h on day 1 of each 14-day cycle), followed by surgery and adjuvant chemotherapy. Patients in the upfront surgery group underwent surgery and then received adjuvant chemotherapy. Initially, adjuvant chemotherapy was gemcitabine plus capecitabine (gemcitabine 1000 mg/m2 over 30 min on days 1, 8, and 15 of each 28-day cycle and capecitabine 830 mg/m2 twice daily for 3 weeks with 1 week of rest in each 28-day cycle; four cycles in the neoadjuvant FOLFIRINOX group, six cycles in the upfront surgery group). A protocol amendment was subsequently made to permit use of adjuvant modified FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2 over 46 h on day 1 of each 14-day cycle; eight cycles in the neoadjuvant FOLFIRINOX group, 12 cycles in the upfront surgery group). Randomisation was performed with a computerised algorithm that stratified for each participating centre and used a concealed block size of two to six. Patients, investigators, and study team members were not masked to treatment allocation. The primary endpoint was overall survival at 18 months. Analyses were done in the intention-to-treat (ITT) and per-protocol populations. Safety was assessed in all patients who were randomly assigned and received at least one cycle of neoadjuvant or adjuvant therapy. This trial is registered with ClinicalTrials.gov, NCT02919787, and EudraCT, 2015-001635-21, and is ongoing. Findings Between Feb 8, 2017, and April 21, 2021, 77 patients were randomly assigned to receive neoadjuvant FOLFIRINOX and 63 to undergo upfront surgery. All patients were included in the ITT analysis. For the per-protocol analysis, 17 (22%) patients were excluded from the neoadjuvant FOLFIRINOX group (ten did not receive neoadjuvant therapy, four did not have pancreatic ductal adenocarcinoma, and three received another neoadjuvant regimen), and eight (13%) were excluded from the upfront surgery group (seven did not have pancreatic ductal adenocarcinoma and one did not undergo surgical exploration). 61 (79%) of 77 patients in the neoadjuvant FOLFIRINOX group received neoadjuvant therapy. The proportion of patients alive at 18 months by ITT was 60% (95% CI 49–71) in the neoadjuvant FOLFIRINOX group versus 73% (62–84) in the upfront surgery group (p=0·032), and median overall survival by ITT was 25·1 months (95% CI 17·2–34·9) versus 38·5 months (27·6–not reached; hazard ratio [HR] 1·52 [95% CI 1·00–2·33], log-rank p=0·050). The proportion of patients alive at 18 months in per-protocol analysis was 57% (95% CI 46–67) in the neoadjuvant FOLFIRINOX group versus 70% (55–83) in the upfront surgery group (p=0·14), and median overall survival in per-protocol population was 23·0 months (95% CI 16·2–34·9) versus 34·4 months (19·4–not reached; HR 1·46 [95% CI 0·99–2·17], log-rank p=0·058). In the safety population, 42 (58%) of 73 patients in the neoadjuvant FOLFIRINOX group and 19 (40%) of 47 patients in the upfront surgery group had at least one grade 3 or worse adverse event. 63 (82%) of 77 patients in the neoadjuvant group and 56 (89%) of 63 patients in the upfront surgery group had resection (p=0·24). One sudden death of unknown cause and one COVID-19-related death occurred after the first cycle of neoadjuvant FOLFIRINOX. Adjuvant chemotherapy was initiated in 51 (86%) of 59 patients with resected pancreatic ductal adenocarcinoma in the neoadjuvant FOLFIRINOX group and 44 (90%) of 49 patients with resected pancreatic ductal adenocarcinoma in the upfront surgery group (p=0·56). Adjuvant modified FOLFIRINOX was given to 13 (25%) patients in the neoadjuvant FOLFIRINOX group and 19 (43%) patients in the upfront surgery group. During adjuvant chemotherapy, neutropenia (11 [22%] patients in the neoadjuvant FOLFIRINOX group and five [11%] in the upfront surgery group) was the most common grade 3 or worse adverse event. Interpretation This phase 2 trial did not show a survival benefit from neoadjuvant FOLFIRINOX in resectable pancreatic ductal adenocarcinoma compared with upfront surgery. Implementation of neoadjuvant FOLFIRINOX was challenging. Future trials on treatment sequencing in resectable pancreatic ductal adenocarcinoma should be biomarker driven.

• Majid, Umair; Bergsland, Christian Holst; Sveen, Anita; Bruun, Jarle; Eilertsen, Ina Andrassy & Bækkevold, Espen Sønderaal [Vis alle 10 forfattere av denne artikkelen] (2024). The prognostic effect of tumor-associated macrophages in stage I-III colorectal cancer depends on T cell infiltration. Cellular Oncology. ISSN 2211-3428. 47(4), s. 1267–1276. doi: 10.1007/s13402-024-00926-w. Fulltekst i vitenarkiv Vis sammendrag

  Background Tumor-associated macrophages (TAMs) are associated with unfavorable patient prognosis in many cancer types. However, TAMs are a heterogeneous cell population and subsets have been shown to activate tumor-infiltrating T cells and confer a good patient prognosis. Data on the prognostic value of TAMs in colorectal cancer are conflicting. We investigated the prognostic effect of TAMs in relation to tumor-infiltrating T cells in colorectal cancers. Methods The TAM markers CD68 and CD163 were analyzed by multiplex fluorescence immunohistochemistry and digital image analysis on tissue microarrays of 1720 primary colorectal cancers. TAM density in the tumor stroma was scored in relation to T cell density (stromal CD3+ and epithelial CD8+ cells) and analyzed in Cox proportional hazards models of 5-year relapse-free survival. Multivariable survival models included clinicopathological factors, MSI status and BRAFV600E mutation status. Results High TAM density was associated with a favorable 5-year relapse-free survival in a multivariable model of patients with stage I–III tumors (p = 0.004, hazard ratio 0.94, 95% confidence interval 0.90–0.98). However, the prognostic effect was dependent on tumoral T-cell density. High TAM density was associated with a good prognosis in patients who also had high T-cell levels in their tumors, while high TAM density was associated with poorer prognosis in patients with low T-cell levels (pinteraction = 0.0006). This prognostic heterogeneity was found for microsatellite stable tumors separately. Conclusions This study supported a phenotypic heterogeneity of TAMs in colorectal cancer, and showed that combined tumor immunophenotyping of multiple immune cell types improved the prediction of patient prognosis.

• Saeed, Usman; Yakub, Sheraz; Barreto, Savio G.; Pandol, Stephen & Mala, Tom (2024). Reducing the risk of cancer with bariatric surgery: The need for evidence to guide practice. Scandinavian Journal of Surgery. ISSN 1457-4969. s. 263–335. doi: 10.1177/14574969241264064. Fulltekst i vitenarkiv
• Jensenius, Mogens; Mørch, Kristine; Yakub, Sheraz; Halvorsen, Dag Seeger; Reims, Henrik Mikael & Björk, Ida Gabriella [Vis alle 11 forfattere av denne artikkelen] (2024). Alveolær ekinokokkose. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 144(10). doi: 10.4045/tidsskr.24.0121. Fulltekst i vitenarkiv
• Aune, Dagfinn; Nordsletten, Marie Wiborg; Myklebust, Tor Åge; Robsahm, Trude Eid; Skålhegg, Bjørn Steen & Mala, Tom [Vis alle 8 forfattere av denne artikkelen] (2024). The association between body mass index and vulvar and vaginal cancer incidence: findings from a large Norwegian cohort study. Cancer Causes and Control. ISSN 0957-5243. 36, s. 191–198. doi: 10.1007/s10552-024-01930-z. Fulltekst i vitenarkiv Vis sammendrag

  Background There is limited evidence of potential associations between body mass index (BMI) and risk of vulvar and vaginal cancer. We explored these associations in a large cohort of Norwegian women. Methods The analytical dataset included 889,441 women aged 16–75 years at baseline in 1963–1975. Multivariable Cox regression analyses were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between BMI and vulvar and vaginal cancer incidence. Results During 30.1 million person-years of follow-up, 1748 incident vulvar and 408 incident vaginal cancer cases occurred. The HRs (95% CIs) for vulvar cancer for a BMI of 15- < 18.5, 18.5- < 25, 25- < 30, 30- < 35, ≥ 35 were 0.62 (0.38–1.01), 1.00 (reference), 1.23 (1.10–1.40), 1.43 (1.23–1.66) and 1.72 (1.35–2.20, ptrend < 0.001), and per 5 kg/m2 increment was 1.20 (1.13–1.26). The corresponding HRs (95% CIs) for vaginal cancer were 1.05 (0.52–2.15), 1.00, 0.89 (0.71–1.12), 0.95 (0.68–1.34), and 2.01 (1.29–3.13, ptrend < 0.001), respectively, and per 5 kg/m2 was 1.11 (0.99–1.25). The HR (95% CI) per 5 kg/m2 increase in BMI at ages 16–29 was 1.28 (1.07–1.54, n = 250 cases) for vulvar and 1.53 (1.11–2.11, n = 66 cases) for vaginal cancers. The HR (95% CI) per 5 kg/m2 for early-onset (< 50 years age at diagnosis) vulvar cancer was 0.92 (0.66–1.28, n = 87 cases) and 1.70 (1.05–2.76, n = 21 cases) for vaginal cancer. Conclusion These results further support the associations between higher BMI and increased risk of vulvar and vaginal cancers, with suggestive stronger associations between BMI in early adulthood for both cancers and for early-onset vaginal cancer. Further studies are needed to elucidate these findings and investigate the underlying mechanisms.

• Lluís, Núria; Onoe, Shunsuke; Serradilla-Martín, Mario; Achalandabaso, Mar; Mizuno, Takashi & Jehaes, François [Vis alle 41 forfattere av denne artikkelen] (2024). Intraductal papillary neoplasms of the bile ducts: a comparative study of a rare disease in Europe and Nagoya, Japan. HPB. ISSN 1365-182X. 26(4), s. 565–575. doi: 10.1016/j.hpb.2024.01.009. Fulltekst i vitenarkiv
• Aune, Dagfinn; Nordsletten, Marie Wiborg; Myklebust, Tor Åge; Robsahm, Trude Eid; Skålhegg, Bjørn Steen & Mala, Tom [Vis alle 8 forfattere av denne artikkelen] (2024). Body mass index and penile cancer incidence: results from a Norwegian cohort study of 829,081 men. BMC Urology. 24(1), s. 1–6. doi: 10.1186/s12894-024-01636-z. Fulltekst i vitenarkiv Vis sammendrag

  Background A few previous studies have suggested a possible association between adiposity and increased risk of penile cancer, however, the evidence is to date limited for this rare cancer. We investigated the association between body mass index (BMI) and penile cancer risk in a large Norwegian cohort. Methods The analyses included 829,081 men aged 16–75 years at baseline in 1963–1975. Multivariable Cox regression analyses were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between BMI and penile cancer incidence. Results A total of 725 incident penile cancer cases occurred during 25.6 million person-years of follow-up. Compared to men with BMI 18.5-<25, the HRs (95% CIs) of those with a BMI of 15-<18.5, 25-<30, and ≥ 30 were 0.45 (0.15–1.41), 1.14 (0.97–1.33) and 1.63 (1.20–2.22), respectively, and the HR was 1.26 (1.12–1.42) per 5 kg/m2 increase in BMI. When the obese category was further subdivided in grade 1 (BMI 30-<35) and grade 2 obesity (≥ 35), the respe

• Riis, Åse Garløv; Jensenius, Mogens; Greve, Ole Jacob; Lier, Tore; Nylenna, Øyvind & Yakub, Sheraz (2024). Rumpert ekinokokkcyste. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 144(9). doi: 10.4045/tidsskr.23.0727. Fulltekst i vitenarkiv
• Grimsrud, Marit Mæhle; Forster, Michael; Goeppert, Benjamin; Hemmrich-Stanisak, Georg; Sax, Irmi & Grzyb, Krzysztof [Vis alle 21 forfattere av denne artikkelen] (2024). Whole-exome sequencing reveals novel cancer genes and actionable targets in biliary tract cancers in primary sclerosing cholangitis. Hepatology communications.. 8(7). doi: 10.1097/HC9.0000000000000461. Fulltekst i vitenarkiv Vis sammendrag

  Background: People with primary sclerosing cholangitis (PSC) have a 20% lifetime risk of biliary tract cancer (BTC). Using whole-exome sequencing, we characterized genomic alterations in tissue samples from BTC with underlying PSC. Methods: We extracted DNA from formalin-fixed, paraffin-embedded tumor and paired nontumor tissue from 52 resection or biopsy specimens from patients with PSC and BTC and performed whole-exome sequencing. Following copy number analysis, variant calling, and filtering, putative PSC-BTC-associated genes were assessed by pathway analyses and annotated to targeted cancer therapies. Results: We identified 53 candidate cancer genes with a total of 123 nonsynonymous alterations passing filtering thresholds in 2 or more samples. Of the identified genes, 19% had not previously been implicated in BTC, including CNGA3, KRT28, and EFCAB5. Another subset comprised genes previously implicated in hepato-pancreato-biliary cancer, such as ARID2, ELF3, and PTPRD. Finally, we identified a subset of genes implicated in a wide range of cancers such as the tumor suppressor genes TP53, CDKN2A, SMAD4, and RNF43 and the oncogenes KRAS, ERBB2, and BRAF. Focal copy number variations were found in 51.9% of the samples. Alterations in potential actionable genes, including ERBB2, MDM2, and FGFR3 were identified and alterations in the RTK/RAS (p = 0.036), TP53 (p = 0.04), and PI3K (p = 0.043) pathways were significantly associated with reduced overall survival. Conclusions: In this exome-wide characterization of PSC-associated BTC, we delineated both PSC-specific and universal cancer genes. Our findings provide opportunities for a better understanding of the development of BTC in PSC and could be used as a platform to develop personalized treatment approaches.

• Dagenborg, Vegar Johansen; Brudvik, Kristoffer Watten; Lund-Andersen, Christin; Kristensen, Annette Torgunrud; Lund-Iversen, Marius & Flatmark, Kjersti [Vis alle 8 forfattere av denne artikkelen] (2024). Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy and Liver Resection is a Treatment Option for Patients with Peritoneal and Liver Metastases from Colorectal Cancer. Annals of Surgery. ISSN 0003-4932. 280(5), s. 745–752. doi: 10.1097/SLA.0000000000006492. Fulltekst i vitenarkiv Vis sammendrag

  Objective: To study outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) in patients also treated for colorectal liver metastases (CLM). Background: Colorectal cancer (CRC) frequently metastasizes to the liver and peritoneum and is associated with a poor prognosis. In selected patients, a benefit in overall survival (OS) was shown for both peritoneal metastases (PM-CRC) offered CRS-HIPEC, and CLM treated with surgical resection. However, the presence of CLM was considered a relative contraindication to CRS-HIPEC, causing a paucity of outcome data in this patient group. Methods: Patients with PM-CRC having CRS-HIPEC at a single national center between 2007 and 2023, with additional intervention for CLM, were included (previous curative treatment for extraperitoneal and extrahepatic metastases was allowed). Three groups were defined: CLM before CRS-HIPEC (pre-CRS-HIPEC), CLM resected simultaneously with CRS-HIPEC (sim-CRS-HIPEC), and CLM after CRS-HIPEC (post-CRS-HIPEC), aiming to retrospectively analyze outcomes. Results: Fifty-seven patients were included and classified as: pre-CRS-HIPEC (n = 11), sim-CRS-HIPEC (n = 29), and post-CRS-HIPEC (n = 17). Median Peritoneal Cancer Index (PCI) was 8; 13 patients had severe complications (Clavien-Dindo ≥3), and no 90-day mortality. Median OS was 48 months after CRS-HIPEC. PCI was a predictor of OS (hazard ratio: 1.11, P < 0.001). We observed no difference in short or long-term outcomes between intervention groups. Discussion: This study demonstrated that patients with CLM having CRS-HIPEC had comparable OS to reports on CRS-HIPEC only, likely explained by a low PCI. Simultaneous CLM resection did not increase the risk of severe complications. Conclusions: In this national cohort, CRS-HIPEC and CLM intervention offers long-term survival, suggesting that this treatment may be offered to selected patients with PM-CRC and CLM.

• Lluís, Núria; Serradilla-Martín, Mario; Achalandabaso, Mar; Jehaes, François; Dasari, Bobby V M & Mambrilla-Herrero, Sara [Vis alle 38 forfattere av denne artikkelen] (2023). Intraductal papillary neoplasms of the bile duct: a European retrospective multicenter observational study (EUR-IPNB study). International Journal of Surgery (IJS). ISSN 1743-9191. 109(4), s. 760–771. doi: 10.1097/JS9.0000000000000280. Fulltekst i vitenarkiv Vis sammendrag

  Background/Purpose: Intraductal papillary neoplasm of the bile duct (IPNB) is a rare disease in Western countries. The main aim of this study was to characterize current surgical strategies and outcomes in the mainly European participating centers. Methods: A multi-institutional retrospective series of patients with a diagnosis of IPNB undergoing surgery between 1 January 2010 and 31 December 2020 was gathered under the auspices of the European-African Hepato-Pancreato-Biliary Association. The textbook outcome (TO) was defined as a non-prolonged length of hospital stay plus the absence of any Clavien–Dindo grade at least III complications, readmission, or mortality within 90 postoperative days. Results: A total of 28 centers contributed 85 patients who underwent surgery for IPNB. The median age was 66 years (55–72), 49.4% were women, and 87.1% were Caucasian. Open surgery was performed in 72 patients (84.7%) and laparoscopic in 13 (15.3%). TO was achieved in 54.1% of patients, reaching 63.8% after liver resection and 32.0% after pancreas resection. Median overall survival was 5.72 years, with 5-year overall survival of 63% (95% CI: 50–82). Overall survival was better in patients with Charlson comorbidity score 4 or less versus more than 4 (P=0.016), intrahepatic versus extrahepatic tumor (P=0.027), single versus multiple tumors (P=0.007), those who underwent hepatic versus pancreatic resection (P=0.017), or achieved versus failed TO (P=0.029). Multivariable Cox regression analysis showed that not achieving TO (HR: 4.20; 95% CI: 1.11–15.94; P=0.03) was an independent prognostic factor of poor overall survival. Conclusions: Patients undergoing liver resection for IPNB were more likely to achieve a TO outcome than those requiring a pancreatic resection. Comorbidity, tumor location, and tumor multiplicity influenced overall survival. TO was an independent prognostic factor of overall survival.

• Saeed, Usman; Nordsletten, Marie Wiborg; Myklebust, Tor Åge; Robsahm, Trude Eid; Møller, Bjørn & Skålhegg, Bjørn Steen [Vis alle 8 forfattere av denne artikkelen] (2023). Cancer risk and survival according to body mass index in hepatobiliary malignancies: a nationwide registry-based cohort study. HPB. ISSN 1365-182X. 25(11), s. 1382–1392. doi: 10.1016/j.hpb.2023.07.882. Fulltekst i vitenarkiv Vis sammendrag

  Background The aim of this study was to explore the associations between BMI and cancer of the liver, bile ducts, and gallbladder. Methods A registry-based cohort study was performed by linking data from several national registries in Norway. Results The cohort comprised 1 723 692 individuals including 4768 hepatobiliary cancer cases during 55 743 509 person-years of follow-up. In men, we found increased risk of cancer per 5 kg/m2 BMI increase for hepatocellular carcinoma and extrahepatic cholangiocarcinoma. In women there was increased risk of extrahepatic cholangiocarcinoma and gallbladder cancer. Women with high BMI in early adulthood had increased risk of intrahepatic cholangiocarcinoma. Reduced cancer-specific survival was found for all hepatobiliary malignancies in women with overweight and obesity. In men, reduced survival was observed in individuals with obesity for all hepatobiliary cancers, except gallbladder cancer. Increased risk of cancer-death per 5 kg/m2 BMI increase was found for hepatocellular carcinoma, intra-, and extrahepatic cholangiocarcinoma in women. For men, 5 kg/m2 BMI increase was positively associated with cancer-death from intrahepatic cholangiocarcinoma. Discussion This study supports the notion of an increased risk of hepatobiliary cancers with increasing BMI, with sex and age variations. The findings also suggest a higher risk of cancer-death with increasing BMI.

• Ghotbi, Jacob; Yakub, Sheraz & Søreide, Kjetil (2023). Management of extrahepatic bile duct cysts. British Journal of Surgery. ISSN 0007-1323. 110(10), s. 1252–1255. doi: 10.1093/bjs/znad087. Fulltekst i vitenarkiv
• Kjeseth, Trond; Yakub, Sheraz; Edwin, Bjørn von Gohren; Kleive, Dyre & Sahakyan, Mushegh (2023). Peri-firing compression in prevention of pancreatic fistula after distal pancreatectomy: A systematic review and a cohort study. Scandinavian Journal of Surgery. ISSN 1457-4969. doi: 10.1177/14574969231211084. Fulltekst i vitenarkiv Vis sammendrag

  Background/Aims: Clinically relevant postoperative pancreatic fistula (CR-POPF) after distal pancreatectomy (DP) occurs in 20%–40% of patients and remains a leading cause of morbidity and increased healthcare cost in this patient group. Recently, several studies suggested decreased risk of CR-POPF with the use of peri-firing compression (PFC) technique. The aim of this report was to conduct a systematic review to get an overview of the current knowledge on the use of PFC in DP. In addition, our experience with PFC was presented. Methods: The systematic literature review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Also, 19 patients undergoing DP with the use of PFC at Oslo University Hospital were studied. The primary endpoint was incidence of CR-POPF. Results: Seven articles reporting a total of 771 patients were ultimately included in the systematic review. Only two of these were case–control studies examining outcomes in patients with and without PFC, while the rest were case series. These were heterogeneous in terms of staplers used, cartridge selection policy, and PFC technique. Both case–control studies reported significantly reduced CR- POPF incidence with PFC. Eight (21%) of our patients developed CR-POPF after DP with PFC. Only one patient developed CR-POPF among those with pancreatic transection site thickness ⩽1.5 cm. Conclusion: Evidence on potential benefits of PFC in DP is limited in quantity and quality. Our findings suggest that the use of PFC does not lead to reduction in the incidence of CR-POPF. Yet, there might be a benefit from PFC when dealing with a thin pancreas.

• Yakub, Sheraz; Margonis, Georgios Antonios & Søreide, Kjetil (2023). Staged or Simultaneous Surgery for Colon or Rectal Cancer with Synchronous Liver Metastases: Implications for Study Design and Clinical Endpoints. Cancers. 15(7). doi: 10.3390/cancers15072177. Fulltekst i vitenarkiv Vis sammendrag

  In patients presenting with colorectal cancer and synchronous liver metastases, the disease burden related to the liver metastasis is the driving cause of limited longevity and, eventually, risk of death. Surgical resection is the potentially curative treatment for colorectal cancer liver metastases. In the synchronous setting where both the liver metastases and the primary tumor are resectable with a relative low risk, the oncological surgeon and the patient may consider three potential treatment strategies. Firstly, a “staged” or a “simultaneous” surgical approach. Secondly, for a staged strategy, a ‘conventional approach’ will suggest removal of the primary tumor first (either colon or rectal cancer) and plan for liver surgery after recovery from the first operation. A “Liver first” strategy is prioritizing the liver resection before resection of the primary tumor. Planning a surgical trial investigating a two-organ oncological resection with highly variable extent and complexity of resection as well as the potential impact of perioperative chemo(radio)therapy makes it difficult to find the optimal primary endpoint. Here, we suggest running investigational trials with carefully chosen composite endpoints as well as embedded risk-stratification strategies to identify subgroups of patients who may benefit from simultaneous surgery.

• Yakub, Sheraz; Tholfsen, Tore; Waage, Anne; Kleive, Dyre & Labori, Knut Jørgen (2023). Pancreatoduodenectomy after Roux-en-Y gastric bypass surgery: Single-center experience and literature review. Scandinavian Journal of Surgery. ISSN 1457-4969. 112, s. 98–104. doi: 10.1177/14574969231156350. Fulltekst i vitenarkiv Vis sammendrag

  Background and objective: Bariatric surgery with Roux-en-Y gastric bypass (RYGB) is widely used to treat morbid obesity and present diagnostic and therapeutic challenges in patients with pancreatic and periampullary tumors. The aim of this study was to describe diagnostic tools and challenges in performing pancreatoduodenectomy (PD) on patients with altered anatomy after RYGB. Methods: Patients undergoing PD after RYGB from April 2015 to June 2022 at a tertiary referral center were identified. Preoperative workup, operative techniques, and outcomes were reviewed. A literature search was performed to identify articles reporting PD in post-RYGB patients. Results: Of a total of 788 PDs, six patients had previous RYGB. The majority were women (n = 5), and median age was 59 years. The patients most commonly presented with pain (50%) and jaundice (50%) with a median of 5.5 years after RYGB. The gastric remnant was resected in all cases, and reconstruction of the pancreatobiliary drainage was achieved using the distal part of the pre-existing pancreatobiliary limb in all patients. Median follow-up was 60 months. The Clavien–Dindo grade ⩾3 complications occurred in two patients (33.3%), and 90 days mortality occurred in one patient (16.6%). The literature search revealed 9 articles reporting a total of 122 cases, specifically addressing PD after RYGB. Conclusions: Reconstruction after PD in post-RYGB patients may be challenging. Resection of the gastric remnant and use of the pre-existing biliopancreatic limb may be a safe strategy, but surgeons should be prepared for other reconstruction options for creation of a new pancreatobiliary limb.

• Nordsletten, Marie Wiborg; Saeed, Usman; Myklebust, Tor Åge; Robsahm, Trude Eid; Møller, Bjørn & Skålhegg, Bjørn Steen [Vis alle 8 forfattere av denne artikkelen] (2023). Body mass index and its association with 22 cancer types: a Norwegian cohort study of 481 202 cancer cases. Acta Oncologica. ISSN 0284-186X. 62(10), s. 1273–1278. doi: 10.1080/0284186X.2023.2258443. Fulltekst i vitenarkiv
• Azhar, Najia; Lambrichts, Daniël; Lange, Johan; Yakub, Sheraz; Øresland, Tom & Schultz, Johannes Kurt [Vis alle 8 forfattere av denne artikkelen] (2023). Laparoscopic lavage for Hinchey III perforated diverticulitis: factors for treatment failure in two randomized clinical trials. British Journal of Surgery. ISSN 0007-1323. 110(7), s. 846–851. doi: 10.1093/bjs/znad114. Fulltekst i vitenarkiv Vis sammendrag

  Abstract Background The Scandinavian Diverticulitis (SCANDIV) trial and the LOLA arm of the LADIES trial randomized patients with Hinchey III perforated diverticulitis to laparoscopic peritoneal lavage or sigmoid resection. The aim of this analysis was to identify risk factors for treatment failure in patients with Hinchey III perforated diverticulitis. Methods This was a post hoc analysis of the SCANDIV trial and LOLA arm. Treatment failure was defined as morbidity requiring general anaesthesia (Clavien–Dindo grade IIIb or higher) within 90 days. Age, sex, BMI, ASA fitness grade, smoking status, previous episodes of diverticulitis, previous abdominal surgery, time to surgery, and surgical competence were all tested in univariable and multivariable logistic regression analyses using an interaction variable. Results The pooled analysis included 222 patients randomized to laparoscopic lavage and primary resection (116 and 106 patients respectively). Univariable analysis found ASA grade to be associated with advanced morbidity in both groups, and the following factors in the laparoscopic lavage group: smoking, corticosteroid use, and BMI. Significant factors for laparoscopic lavage morbidity in multivariable analysis were smoking (OR 7.05, 95 per cent c.i. 2.07 to 23.98; P = 0.002) and corticosteroid use (OR 6.02, 1.54 to 23.51; P = 0.010). Conclusion Active smoking status and corticosteroid use were risk factors for laparoscopic lavage treatment failure (advanced morbidity) in patients with perforated diverticulitis.

• Chauhan, Sudhir Kumar; Casado, Raquel Bartolome; Landsverk, Ole J. B.; Johannessen, Hanna; Phung, Danh Thanh & Nilsen, Hogne Røed [Vis alle 14 forfattere av denne artikkelen] (2023). Human small intestine contains 2 functionally distinct regulatory T-cell subsets. Journal of Allergy and Clinical Immunology. ISSN 0091-6749. 152(1), s. 278–289.e6. doi: 10.1016/j.jaci.2023.02.030. Fulltekst i vitenarkiv Vis sammendrag

  Background Regulatory T (Treg) CD4 cells in mouse gut are mainly specific for intestinal antigens and play an important role in the suppression of immune responses against harmless dietary antigens and members of the microbiota. However, information about the phenotype and function of Treg cells in the human gut is limited. Objective We performed a detailed characterization of Foxp3+ CD4 Treg cells in human normal small intestine (SI) as well as from transplanted duodenum and celiac disease lesions. Methods Treg cells and conventional CD4 T cells derived from SI were subjected to extensive immunophenotyping and their suppressive activity and ability to produce cytokines assessed. Results SI Foxp3+ CD4 T cells were CD45RA−CD127−CTLA-4+ and suppressed proliferation of autologous T cells. Approximately 60% of Treg cells expressed the transcription factor Helios. When stimulated, Helios-negative Treg cells produced IL-17, IFN-γ, and IL-10, whereas Helios-positive Treg cells produced very low levels of these cytokines. By sampling mucosal tissue from transplanted human duodenum, we demonstrated that donor Helios-negative Treg cells persisted for at least 1 year after transplantation. In normal SI, Foxp3+ Treg cells constituted only 2% of all CD4 T cells, while in active celiac disease, both Helios-negative and Helios-positive subsets expanded 5- to 10-fold. Conclusion The SI contains 2 subsets of Treg cells with different phenotypes and functional capacities. Both subsets are scarce in healthy gut but increase dramatically in active celiac disease.

• Saaed, Usman; Myklebust, Tor Åge; Robsahm, Trude Eid; Møller, Bjørn; Mala, Tom & Skålhegg, Bjørn Steen [Vis alle 7 forfattere av denne artikkelen] (2022). Body mass index and pancreatic adenocarcinoma: A nationwide registry-based cohort study. Scandinavian Journal of Surgery. ISSN 1457-4969. 112(1), s. 11–21. doi: 10.1177/14574969221127530. Fulltekst i vitenarkiv Vis sammendrag

  Background and objective:An association between body mass index (BMI) and pancreatic cancer is suggested in observational studies. However, further studies are required to substantiate available evidence. The aim of this study was to explore the association between BMI and pancreatic ductal adenocarcinoma (PDAC) risk, treatment, and mortality. Methods:A registry-based cohort study was performed by combining data from four registries in Norway. Baseline data were collected between 1963 and 1975 with follow-up data collected until 2018. Kaplan–Meier curves and multivariable Cox regressions were estimated. Chi-square tests were used to analyze differences between groups. Results:The study cohort consisted of 1,723,692 individuals. A total of 8973 PDAC cases were identified during 55,744,749 person-years of follow-up. A 5 kg/m2 increase in BMI was associated with an increased risk of PDAC if high BMI at young age (16–29 years) (hazard ratio (HR): 1.21, 95% confidence interval (CI): 1.13–1.31), both for men (HR: 1.30, 95% CI: 1.15–1.46) and women (HR: 1.16, 95% CI: 1.05–1.28). In men, there was a 52% increase in risk of early-onset PDAC (<age 50) (HR: 1.52, 95% CI: 1.13-2.03) with 5 kg/m2 increase in BMI. A total of 2645 individuals were diagnosed with stage 1–3 disease, of whom 1131 underwent curative surgery. In all, 49% of normal weight, 38% overweight, and 30% obese individuals with stage 1–3 PDAC underwent surgery with curative intent (p < 0.001). Cancer survival was lower in overweight and obese individuals for both sexes. Analysis adjusted for sex, age, and period of diagnosis confirmed increased risk of cancer death in obese individuals. Conclusion:This study suggests that increased BMI in young adults may increase the risk of PDAC, and higher BMI in men is associated with an increased risk of early onset PDAC (<age 50). Overweight and obese individuals were less likely to undergo curative surgery and obese individuals had a higher risk of cancer-related death.

• Saaed, Usman; Myklebust, Tor Åge; Robsahm, Trude Eid; Kielland, Marlene Fritsch; Møller, Bjørn & Skålhegg, Bjørn Steen [Vis alle 8 forfattere av denne artikkelen] (2022). Risk and survival in colorectal cancer with increasing body mass index: A nationwide population-based cohort study. Colorectal Disease. ISSN 1462-8910. s. 1–11. doi: 10.1111/codi.16367. Fulltekst i vitenarkiv Vis sammendrag

  Aim: The aim was to explore potential associations between the body mass index (BMI) and the risk of colorectal cancer (CRC), including subsites of the colon, and cancer-specific death. Methods: A registry-based cohort study was conducted with baseline data gathered from the Norwegian Tuberculosis Screening Programme, collected between 1963 and 1975, and linked to follow-up data from the Cancer Registry of Norway and the Norwegian Cause of Death Registry. Cox regression models were used to explore associations between BMI and CRC risk and cancer-specific death. Results: Of 1 723 692 included individuals, 76 616 developed CRC during 55 370 707 person-years of follow-up. In men, a 5 kg/m2 increase in BMI was associated with an increased risk of colon cancer, including both right and left subsites, and rectal cancer. Allowing for nonlinearities, we found a U-shaped association for the right colon and an inverse U-shape for the left colon and rectum cancer. In women, a 5 kg/m2 increase in BMI in early adulthood was associated with increased risk of colon cancer, including both subsites. In women, an increased risk of CRC death with increasing BMI was found for colon cancer. Conclusions: Men of all ages have an increased risk of CRC with increasing BMI, with the highest risk for right-sided colon cancer. An increased risk for colon cancer was also found in women with high BMI in early adulthood. Furthermore, women of all age groups appeared to have an increased risk of CRC death with higher BMI.

• Aghayan, Davit; d’Albenzio, Gabriella; Fretland, Åsmund Avdem; Pelanis, Egidijus; Røsok, Bård Ingvald & Yaqub, Sheraz [Vis alle 8 forfattere av denne artikkelen] (2022). Laparoscopic parenchyma-sparing liver resection for large (≥ 50 mm) colorectal metastases. Surgical Endoscopy. ISSN 0930-2794. 37, s. 225–233. doi: 10.1007/s00464-022-09493-3. Fulltekst i vitenarkiv Vis sammendrag

  Abstract Background Traditionally, patients with large liver tumors (≥ 50 mm) have been considered for anatomic major hepatectomy. Laparoscopic resection of large liver lesions is technically challenging and often performed by surgeons with extensive experience. The current study aimed to evaluate the surgical and oncologic safety of laparoscopic parenchyma-sparing liver resection in patients with large colorectal metastases. Methods Patients who primarily underwent laparoscopic parenchyma-sparing liver resection (less than 3 consecutive liver segments) for colorectal liver metastases between 1999 and 2019 at Oslo University Hospital were analyzed. In some recent cases, a computer-assisted surgical planning system was used to better visualize and understand the patients’ liver anatomy, as well as a tool to further improve the resection strategy. The surgical and oncologic outcomes of patients with large (≥ 50 mm) and small (&lt; 50 mm) tumors were compared. Multivariable Cox-regression analysis was performed to identify risk factors for survival. Results In total 587 patients met the inclusion criteria (large tumor group, n  = 59; and small tumor group, n  = 528). Median tumor size was 60 mm (range, 50–110) in the large tumor group and 21 mm (3–48) in the small tumor group ( p  &lt; 0.001). Patient age and CEA level were higher in the large tumor group (8.4 μg/L vs. 4.6 μg/L, p  &lt; 0.001). Operation time and conversion rate were similar, while median blood loss was higher in the large tumor group (500 ml vs. 200 ml, p  &lt; 0.001). Patients in the large tumor group had shorter 5 year overall survival (34% vs 49%, p  = 0.027). However, in the multivariable Cox-regression analysis tumor size did not impact survival, unlike parameters such as age, ASA score, CEA level, extrahepatic disease at liver surgery, and positive lymph nodes in the primary tumor. Conclusion Laparoscopic parenchyma-sparing resections for large colorectal liver metastases provide satisfactory short and long-term outcomes. Graphical abstract

• Sahakyan, Mushegh; Aghayan, Davit; Edwin, Bjørn von Gohren; Alikhanov, Ruslan; Britskaia, Natalia & Brudvik, Kristoffer Watten [Vis alle 20 forfattere av denne artikkelen] (2022). Laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma: a multicenter propensity score-matched study. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. doi: 10.1080/00365521.2022.2143724. Fulltekst i vitenarkiv Vis sammendrag

  Background: The role of laparoscopy in the treatment of intrahepatic cholangiocarcinoma (ICC) remains unclear. This multicenter study examined the outcomes of laparoscopic liver resection for ICC.<p> <p>Methods: Patients with ICC who had undergone laparoscopic or open liver resection between 2012 and 2019 at four European expert centers were included in the study. Laparoscopic and open approaches were compared in terms of surgical and oncological outcomes. Propensity score matching was used for minimizing treatment selection bias and adjusting for confounders (age, ASA grade, tumor size, location, number of tumors and underlying liver disease). <p>Results: Of 136 patients, 50 (36.7%) underwent laparoscopic resection, whereas 86 (63.3%) had open surgery. Median tumor size was larger (73.6 vs 55.1 mm, p¼ 0.01) and the incidence of bi-lobar tumors was higher (36.6 vs 6%, p< 0.01) in patients undergoing open surgery. After propensity score matching baseline characteristics were comparable although open surgery was associated with a larger fraction of major liver resections (74 vs 38%, p< 0.01), lymphadenectomy (60 vs 20%, p< 0.01) and longer operative time (294 vs 209 min, p< 0.01). Tumor characteristics were similar. Laparoscopic resection resulted in less complications (30 vs 52%, p¼ 0.025), fewer reoperations (4 vs 16%, p¼ 0.046) and shorter hospital stay (5 vs 8 days, p< 0.01). No differences were found in terms of recurrence, recurrence-free and overall survival. <p>Conclusion: Laparoscopic resection seems to be associated with improved short-term and with similar long-term outcomes compared with open surgery in patients with ICC. However, possible selection criteria for laparoscopic surgery are yet to be defined.

• Ghotbi, Jacob; Sahakyan, Mushegh; Søreide, Kjetil; Fretland, Åsmund Avdem; Røsok, Bård Ingvald & Tholfsen, Tore [Vis alle 11 forfattere av denne artikkelen] (2022). Minimally Invasive Pancreatoduodenectomy: Contemporary Practice, Evidence, and Knowledge Gaps. Oncology and Therapy. ISSN 2366-1070. 10(2). doi: 10.1007/s40487-022-00203-6. Fulltekst i vitenarkiv Vis sammendrag

  Minimally invasive pancreatoduodenectomy has gained popularity throughout the last decade. For laparoscopic pancreatoduodenectomy, some high-level evidence exists, but with conflicting results. There are currently no published randomized controlled trials comparing robotic and open pancreatoduodenectomy. Comparative long-term data for patients with pancreatic ductal adenocarcinoma is lacking to date. Based on the existing evidence, current observed benefits of minimally invasive pancreatoduodenectomy over open pancreatoduodenectomy seem scarce, but retrospective data indicate the safety of these procedures in selected patients. As familiarity with the robotic platform increases, studies have shown an expansion in indications, also including patients with vascular involvement and even indicating favorable results in patients with obesity and high-risk morphometric features. Several ongoing randomized controlled trials aim to investigate potential differences in short- and long-term outcomes between minimally invasive and open pancreatoduodenectomy. Their results are much awaited.

• Sparrelid, Ernesto; Thorsen, Trygve; Sauter, Christina; Jorns, Carl; Stål, Per & Nordin, Arno [Vis alle 14 forfattere av denne artikkelen] (2022). Liver transplantation in patients with post-hepatectomy liver failure – A Northern European multicenter cohort study. HPB. ISSN 1365-182X. doi: 10.1016/j.hpb.2021.12.005. Fulltekst i vitenarkiv Vis sammendrag

  Background Liver transplantation (LTX) has been described as a rescue treatment option in severe, intractable post-hepatectomy liver failure (PHLF), but is not considered to be indicated for this condition by many hepatobiliary and transplant surgeons. In this article we describe the clinical experience of five northern European tertiary centers in using LTX to treat selected patients with severe PHLF. Methods All patients subjected to LTX due to PHLF at the participating centers were identified from prospective clinical databases. Preoperative variables, surgical outcome (both resection surgery and LTX) and follow-up data were assessed. Results A total of 10 patients treated with LTX due to severe PHLF from September 2008 to May 2020 were identified and included in the study. All patients but one were male and the median age was 70 years (range 49–72). In all patients the indication for liver resection was suspected malignancy, but in six patients post-resection pathology revealed benign or pre-malignant disease. There was no 90-day mortality after LTX. Patients were followed for a median of 49 months (13–153) and eight patients were alive without recurrence at last follow-up. Discussion In selected patients with PHLF LTX can be a life-saving procedure with low short-term risk.

• Domanska, Diana; Majid, Umair; Karlsen, Victoria; Merok, Marianne Aarstad; Beitnes, Ann-Christin Røberg & Yaqub, Sheraz [Vis alle 8 forfattere av denne artikkelen] (2022). Single-cell transcriptomic analysis of human colonic macrophages reveals niche-specific subsets. Journal of Experimental Medicine (JEM). ISSN 0022-1007. 219:e20211846(3), s. 1–18. doi: 10.1084/jem.20211846. Fulltekst i vitenarkiv Vis sammendrag

  Macrophages are a heterogeneous population of cells involved in tissue homeostasis, inflammation, and cancer. Although macrophages are densely distributed throughout the human intestine, our understanding of how gut macrophages maintain tissue homeostasis is limited. Here we show that colonic lamina propria macrophages (LpMs) and muscularis macrophages (MMs) consist of monocyte-like cells that differentiate into multiple transcriptionally distinct subsets. LpMs comprise subsets with proinflammatory properties and subsets with high antigen-presenting and phagocytic capacity. The latter are strategically positioned close to the surface epithelium. Most MMs differentiate along two trajectories: one that upregulates genes associated with immune activation and angiogenesis, and one that upregulates genes associated with neuronal homeostasis. Importantly, MMs are located adjacent to neurons and vessels. Cell–cell interaction and gene network analysis indicated that survival, migration, transcriptional reprogramming, and niche-specific localization of LpMs and MMs are controlled by an extensive interaction with tissue-resident cells and a few key transcription factors.

• Yaqub, Sheraz; Jensenius, Mogens; Heieren, Ole E. B.; Drolsum, Anders; Pettersen, Frank O. & Labori, Knut Jørgen (2022). Echinococcosis in a non-endemic country–20-years’ surgical experience from a Norwegian tertiary referral Centre. Scandinavian Journal of Gastroenterology. ISSN 0036-5521. 57(8), s. 953–957. doi: 10.1080/00365521.2022.2046846. Fulltekst i vitenarkiv Vis sammendrag

  Background In Scandinavia, the incidence of cystic echinococcosis (CE) and alveolar echinococcosis (AE) is low and almost exclusively an imported disease following the trends of immigration. The aim of the study was to review available data on clinical management and outcome for patients treated at Oslo University Hospital, a referral centre for echinococcosis in Norway, with special emphasis on surgical treatment. Methods All patients admitted with echinococcosis between January 2000 and December 2020 were identified. Medical records were reviewed retrospectively concerning patient demographics, treatment strategy, surgical procedures, complications and outcomes. Results A total of 92 patients with median age 37 years (range 4-85) were identified. Sixty-eight patients (74%) were symptomatic. All patients, except for two, were immigrants to Norway and born in endemic areas. Ninety patients were diagnosed with CE and two with AE. Location of the cysts was most commonly in the liver (86%) followed by peritoneum, lungs, and spleen. All patients with active cysts were treated with albendazole. Surgical treatment was performed in 51 (56%) patients. The most common reason for abstaining from surgical treatment was that the diagnostic work-up revealed inactive cysts or interventional radiology was performed. Of the 51 patients who underwent surgery, a radical procedure was performed in 32 (64%) cases, a conservative procedure in 12 (24%), and a combination in six (12%). Clavien Dindo grade ≥3 complications occurred in 30%, and 90-day mortality was 2%. Bile leakage occurred in seven patients and was treated successfully with endoscopic retrograde cholangiopancreatography with biliary stent placement in all patients. Conclusion In a low-endemic area like Norway, management of echinococcus includes medical therapy, surgery, and/or interventional radiology. Surgical intervention seems to be effective, and is associated with acceptable morbidity rates.

• Dueland, Svein; Yaqub, Sheraz; Syversveen, Trygve; Carling, Johan Ulrik; Hagness, Morten & Brudvik, Kristoffer Watten [Vis alle 7 forfattere av denne artikkelen] (2021). Survival Outcomes after Portal Vein Embolization and Liver Resection Compared with Liver Transplant for Patients with Extensive Colorectal Cancer Liver Metastases. JAMA Surgery. ISSN 2168-6254. 156(6), s. 550–557. doi: 10.1001/jamasurg.2021.0267. Fulltekst i vitenarkiv
• Labori, Knut Jørgen; Tholfsen, Tore; Yaqub, Sheraz; Lassen, Kristoffer; Kleive, Dyre & Waage, Anne (2021). Gastro- or Duodenojejunostomy Leaks After Pancreatoduodenectomy: Single Center Experience and Narrative Literature Review. Journal of Gastrointestinal Surgery. ISSN 1091-255X. s. 1–7. doi: 10.1007/s11605-021-05058-2. Fulltekst i vitenarkiv Vis sammendrag

  <i>Background and Methods</i> - Gastro- or duodenojejunostomy leaks after pancreatoduodenectomy is rare. This study aims to analyze the incidence, management, and outcome of gastro- or duodenojejunostomy leaks after pancreatoduodenectomy based on a single center experience from 2004 to 2020 with a narrative literature review.<br><br> <i>Results</i> - Of a total of 1494 pancreatoduodenectomies, eight patients with gastrojejunostomy (n=1) or duodenojejunostomy (n=7) leak were identified from the institutional pancreatic database. All leaks were treated operatively. In two patients dismantling of the duodenojejunostomy, distal gastrectomy, and closure of the pyloric and jejunal side, a percutaneous endoscopic gastrostomy and a feeding jejunostomy ultimately had to be performed after an unsuccessful attempt of gastrojejunostomy and suture of the duodenojejunostomy, respectively. The literature search revealed three more studies specifically addressing this complication after pancreatoduodenectomy (36 patients of a total of 4739 pancreatoduodenectomies). Based on an analysis of the current study and the literature review, the overall incidence of gastro- or duodenojejunostomy leaks after pancreatoduodenectomy was 0.71 % (44/6233 pancreatoduodenectomies). The occurrence of a gastro- or duodenojejunostomy leak was associated with a concomitant postoperative pancreatic fistula in 50 % of the cases, an increased length of hospital stay, and a mortality rate of 15.9 %. Surgical treatment was performed in 84 % of the cases.<br><br> <i>Conclusion</i> - Gastro- or duodenojejunostomy leak is a rare complication after pancreatoduodenectomy. Prompt diagnosis and early repair is important. In most cases, a surgical intervention is necessary for a good outcome. Under salvage conditions, a bailout strategy may be to temporarily dismantle the gastro- or duodenojejunal anastomosis.

• Kleive, Dyre; Aas, Eline; Angelsen, Jon-Helge; Bringeland, Erling Audun; Nesbakken, Arild & Nymo, Linn Såve [Vis alle 9 forfattere av denne artikkelen] (2021). Simultaneous Resection of Primary Colorectal Cancer and Synchronous Liver Metastases: Contemporary Practice, Evidence and Knowledge Gaps. Oncology and Therapy. ISSN 2366-1070. 9(1), s. 111–120. doi: 10.1007/s40487-021-00148-2. Fulltekst i vitenarkiv Vis sammendrag

  The timing of surgical resection of synchronous liver metastases from colorectal cancer has been debated for decades. Several strategies have been proposed, but high-level evidence remains scarce. Simultaneous resection of the primary tumour and liver metastases has been described in numerous retrospective audits and meta-analyses. The potential benefits of simultaneous resections are the eradication of the tumour burden in one procedure, overall shorter procedure time, reduced hospital stay with the likely benefits on quality of life and an expected reduction in the use of health care services compared to staged procedures. However, concerns about accumulating complications and oncological outcomes remain and the optimal selection criteria for whom simultaneous resections are beneficial remains undetermined. Based on the current level of evidence, simultaneous resection should be restricted to patients with a limited liver tumour burden. More high-level evidence studies are needed to evaluate the quality of life, complication burden, oncological outcomes, as well as overall health care implications for simultaneous resections.

• Dagenborg, Vegar Johansen; Marshall, Serena; Grzyb, Krzysztof; Fretland, Åsmund Avdem; Lund-Iversen, Marius & Mælandsmo, Gunhild Mari [Vis alle 10 forfattere av denne artikkelen] (2021). Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer. Frontiers in Oncology. 11, s. 1–9. doi: 10.3389/fonc.2021.671629. Fulltekst i vitenarkiv Vis sammendrag

  Background: The subtype, density and location of tumor infiltrating T-cells are being explored as prognostic and predictive biomarkers in primary colorectal cancer (pCRC) and colorectal liver metastases (CLM). Very limited data exist comparing findings in pCRC and matched CLM.<p> <p>Patients and methods: Fifty-eight patients with available pCRC and matched CLM (57/58 microsatellite stable) were included in this OSLO-COMET substudy. In immunohistochemically stained sections, total (Ttot), helper (TH), cytotoxic (CTL), and regulatory (Treg) T-cells were manually counted in hotspots from the invasive margin (IM), intratumor (IT), and tumor adjacent regions to determine T-cell densities.<p> <p>Results: A striking accumulation of T-cells was found in IM of both pCRC and CLM with much lower densities in the IT region, exemplified by Ttot of 2838 versus 340 cells/mm2, respectively, in CLM. The correlation at the individual level between T-cell densities in pCRC and corresponding CLM was poor for all regions and T-cell subtypes; for instance, the correlation coefficient (R2) for IM Ttot was 0.07. The IT TH : CTL and Treg : TH ratios were 2.94 and 0.44, respectively, in pCRC, and 1.84 and 0.24, respectively, in CLM.<p> <p>Conclusion: The observed accumulation of T-cells in the IM regions of pCRC and CLM with low penetration to the IT regions, combined with high TH : CTL and Treg : TH ratios, point to the presence of an immune suppressive microenvironment. T-cell densities of CLM differed markedly from the matched pCRC, indicating that to evaluate T-cell biomarkers in metastasis, the commonly available pCRC cannot serve as a surrogate for the metastatic tumor.

• Engstrand, Jennie; Carvalho, Luís Filipe Abreu de; Aghayan, Davit; Balakrishnan, Anita; Belli, Andrea & Bjornsson, Bergthor [Vis alle 38 forfattere av denne artikkelen] (2021). Liver resection and ablation for squamous cell carcinoma liver metastases. BJS Open. doi: 10.1093/bjsopen/zrab060. Fulltekst i vitenarkiv Vis sammendrag

  Abstract Background Limited evidence exists to guide the management of patients with liver metastases from squamous cell carcinoma (SCC). The aim of this retrospective multicentre cohort study was to describe patterns of disease recurrence after liver resection/ablation for SCC liver metastases and factors associated with recurrence-free survival (RFS) and overall survival (OS). Method Members of the European–African Hepato-Pancreato-Biliary Association were invited to include all consecutive patients undergoing liver resection/ablation for SCC liver metastases between 2002 and 2019. Patient, tumour and perioperative characteristics were analysed with regard to RFS and OS. Results Among the 102 patients included from 24 European centres, 56 patients had anal cancer, and 46 patients had SCC from other origin. RFS in patients with anal cancer and non-anal cancer was 16 and 9 months, respectively (P = 0.134). A positive resection margin significantly influenced RFS for both anal cancer and non-anal cancer liver metastases (hazard ratio 6.82, 95 per cent c.i. 2.40 to 19.35, for the entire cohort). Median survival duration and 5-year OS rate among patients with anal cancer and non-anal cancer were 50 months and 45 per cent and 21 months and 25 per cent, respectively. For the entire cohort, only non-radical resection was associated with worse overall survival (hazard ratio 3.21, 95 per cent c.i. 1.24 to 8.30). Conclusion Liver resection/ablation of liver metastases from SCC can result in long-term survival. Survival was superior in treated patients with liver metastases from anal versus non-anal cancer. A negative resection margin is paramount for acceptable outcome.

• Lindholm, Espen; Bergmann, Gisli Björn; Haugaa, Håkon; Labori, Knut Jørgen; Yaqub, Sheraz & Bjørnbeth, Bjørn Atle [Vis alle 11 forfattere av denne artikkelen] (2021). Early detection of anastomotic leakage after pancreatoduodenectomy with microdialysis catheters: an observational Study. HPB. ISSN 1365-182X. 24(6), s. 901–909. doi: 10.1016/j.hpb.2021.10.020. Fulltekst i vitenarkiv Vis sammendrag

  Background Microdialysis catheters can detect focal inflammation and ischemia, and thereby have a potential for early detection of anastomotic leakages after pancreatoduodenectomy. The aim was to investigate whether microdialysis catheters placed near the pancreaticojejunostomy can detect leakage earlier than the current standard of care. Methods Thirty-five patients with a median age 69 years were included. Two microdialysis catheters were placed at the end of surgery; one at the pancreaticojejunostomy, and one at the hepaticojejunostomy. Concentrations of glucose, lactate, pyruvate, and glycerol were analyzed hourly in the microdialysate during the first 24 h, and every 2–4 h thereafter. Results Seven patients with postoperative pancreatic fistulae (POPF) had significantly higher glycerol levels (P < 0.01) in the microdialysate already in the first postoperative samples. Glycerol concentrations >400 μmol/L during the first 12 postoperative hours detected patients with POPF with a sensitivity of 100% and a specificity of 93% (P < 0.001). After 24 h, lactate and lactate-to-pyruvate ratio were significantly higher (P < 0.05) and glucose was significantly lower (P < 0.05) in patients with POPF. Conclusion High levels of glycerol in microdialysate was an early detector of POPF. The subsequent inflammation was detected as increase in lactate and lactate-to-pyruvate ratio and a decrease in glucose (NCT03627559).

• Frick, Rahel; Høydahl, Lene Støkken; Petersen, Jan; Pré, Fleur du; Kumari, Shraddha & Berntsen, Grete [Vis alle 20 forfattere av denne artikkelen] (2021). A high-affinity human TCR-like antibody detects celiac disease gluten peptide-MHC complexes and inhibits T cell activation. Science immunology. 6:eabg4925(62), s. 1–16. doi: 10.1126/sciimmunol.abg4925. Fulltekst i vitenarkiv Vis sammendrag

  Antibodies specific for peptides bound to human leukocyte antigen (HLA) molecules are valuable tools for studies of antigen presentation and may have therapeutic potential. Here, we generated human T cell receptor (TCR)–like antibodies toward the immunodominant signature gluten epitope DQ2.5-glia-α2 in celiac disease (CeD). Phage display selection combined with secondary targeted engineering was used to obtain highly specific antibodies with picomolar affinity. The crystal structure of a Fab fragment of the lead antibody 3.C11 in complex with HLA-DQ2.5:DQ2.5-glia-α2 revealed a binding geometry and interaction mode highly similar to prototypic TCRs specific for the same complex. Assessment of CeD biopsy material confirmed disease specificity and reinforced the notion that abundant plasma cells present antigen in the inflamed CeD gut. Furthermore, 3.C11 specifically inhibited activation and proliferation of gluten-specific CD4+ T cells in vitro and in HLA-DQ2.5 humanized mice, suggesting a potential for targeted intervention without compromising systemic immunity.

• Yaqub, Sheraz; Bjørnbeth, Bjørn Atle; Angelsen, Jon-Helge; Fristrup, Claus W.; Grønbech, Jon Erik & Hemmingsson, Oskar [Vis alle 29 forfattere av denne artikkelen] (2021). Aspirin as secondary prevention in colorectal cancer liver metastasis (ASAC trial): study protocol for a multicentre randomized placebo-controlled trial. Trials. 22(1). doi: 10.1186/s13063-021-05587-w. Fulltekst i vitenarkiv Vis sammendrag

  Background: Colorectal cancer is one the most common cancers in the western world with increasing incidence. Approximately 50% of the patients develop liver metastases. Resection of liver metastases is the treatment of choice although almost half of the resected patients get recurrence in the liver. Methods: The ASAC trial is a Scandinavian, multicentre, double-blinded, randomized, placebo-controlled study to determine whether adjuvant treatment with low-dose aspirin (acetylsalicylic acid (ASA)) can improve disease-free survival in patients treated for colorectal cancer liver metastases (CRCLM). Up to 800 patients operated for CRCLM will be randomized to Arm#1 ASA 160 mg once daily or Arm#2 Placebo, for a period of 3 years or until disease recurrence. The patients will be recruited at all major hepatobiliary surgical units in Norway, Sweden and Denmark and have follow-up according to standard of care and the National Guidelines. Discussion: The ASAC trial will be the first clinical interventional trial to assess the potential beneficial role of ASA in recurrence of CRCLM and survival. ASA is an inexpensive, well-tolerated and easily accessible drug that will be highly potential as adjuvant drug in secondary prevention of CRCLM if the study shows a beneficial effect. We will also determine the effect of ASA as adjuvant treatment on Health-Related Quality of Life and the cost-effectiveness. Trial registration: ClinicalTrials.gov NCT03326791. Registered on 31 October 2017.

• Søreide, Kjetil; Yaqub, Sheraz; Hallet, Julie; Kvaløy, Jan Terje & Kleppe, Tore Selland (2020). A Risk Model of Admitting Patients with Silent SARS-CoV-2 Infection to Surgery and Development of Severe Postoperative Outcomes and Death: Projections Over 24 Months for 5 Geographical Regions. Annals of Surgery. ISSN 0003-4932. 273, s. 208–216. doi: 10.1097/SLA.0000000000004583. Fulltekst i vitenarkiv
• Azhar, Najia; Buchwald, Pamela; Ansari, Hamza; Schyman, Tommy; Yaqub, Sheraz & Øresland, Tom [Vis alle 7 forfattere av denne artikkelen] (2020). Risk of colorectal cancer following CT-verified acute diverticulitis: a nationwide population-based cohort study. Colorectal Disease. ISSN 1462-8910. s. 1406–1414. doi: 10.1111/codi.15073. Fulltekst i vitenarkiv Vis sammendrag

  Aim Routine colonoscopy to exclude colorectal cancer (CRC) after CT‐verified acute diverticulitis is controversial. This study aimed to compare the incidence of CRC in patients with acute diverticulitis with that in the general population. Method Patients with an emergency admission for diverticular disease to any Norwegian hospital between 1 January 2008 and 31 December 2010 were included through identification in the Norwegian Patient Registry using International Classification of Diseases (ICD‐10) codes K57.1‐9. To estimate the age‐specific distribution of CT‐verified acute uncomplicated diverticulitis (AUD) and acute complicated diverticulitis (ACD) in this nationwide study population, numbers from the largest Norwegian emergency hospital were used. Patients diagnosed with CRC within 1 year following their admission for acute diverticulitis were detected through cross‐matching with the Cancer Registry of Norway. Based on both Norwegian age‐specific incidence of CRC and estimated age‐specific distribution of CT‐verified diverticulitis, standard morbidity ratios (SMRs) were calculated. Results A total of 7473 patients with emergency admissions for diverticular disease were identified (estimated CT‐verified AUD n = 3523, ACD n = 1206); of these 155 patients were diagnosed with CRC within 1 year. Eighty had a CT‐verified diverticulitis at index admission [41 AUD (51.3%); 39 ACD (49.7%)]. Compared with the general population, the SMR was 6.6 following CT‐verified AUD and 16.3 following ACD, respectively. Conclusion In the first year after CT‐verified acute diverticulitis, especially after ACD, the risk of CRC is higher than in the general population. This probably represents misdiagnosis of CRC as acute diverticulitis. Follow‐up colonoscopy should be recommended to all patients admitted with acute diverticulitis.

• Dagenborg, Vegar Johansen; Marshall, Serena; Yaqub, Sheraz; Grzyb, Krzysztof; Pedersen, Kjetil Boye & Lund-Iversen, Marius [Vis alle 12 forfattere av denne artikkelen] (2020). Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases. Cancer Biology & Therapy. ISSN 1538-4047. 21(5), s. 432–440. doi: 10.1080/15384047.2020.1721252. Fulltekst i vitenarkiv Vis sammendrag

  Patients with colorectal liver metastases (CLM) commonly receive neoadjuvant chemotherapy (NACT) prior to surgical resection. NACT may induce immunogenic cell death with subsequent recruitment of T-cells to the tumor microenvironment, which could be exploited by immune checkpoint inhibition (ICI). In theory, this could expand the use of ICI to obtain responses also in microsatellite stable colorectal cancer, but evidence to suggest optimal treatment schedules are lacking. In this study, densities of total-, cytotoxic-, helper- and regulatory T-cells were quantified by immunohistochemistry in resected CLM from 92 patients included in the OSLO-COMET trial (NCT01516710). All but one patient had microsatellite stable tumors (91/92). Associations between T-cell densities and clinicopathological parameters were analyzed. Fluoropyrimidine-based NACT (in most cases with addition of oxaliplatin or irinotecan) was administered to 45 patients completed median 8 weeks prior to surgical resection. No overall association was found between NACT administration and intratumoral T-cell densities. However, within the NACT group, a short time interval (<9.5 weeks) between NACT completion and CLM resection was strongly associated with high intratumoral T-cell densities compared to the long-interval and no NACT groups (medians 491, 236, and 292 cells/mm2, respectively; P < .0001). The results from this study suggest that the observed increase in intratumoral T-cells after NACT administration may be transient. The significance of this finding should be further explored to ensure that optimal treatment schedules are chosen for studies combining cytotoxic chemotherapy and ICI.

• Azhar, Najia; Johanssen, Anette; Sundström, Tove; Folkesson, Joakim; Wallon, Conny & Kørner, Hartwig [Vis alle 12 forfattere av denne artikkelen] (2020). Laparoscopic lavage vs primary resection for acute perforated diverticulitis: Long-term outcomes from the Scandinavian Diverticulitis (SCANDIV) randomized clinical trial. JAMA Surgery. ISSN 2168-6254. s. 1–7. doi: 10.1001/jamasurg.2020.5618. Fulltekst i vitenarkiv
• Casado, Raquel Bartolomé; Landsverk, Ole J. B.; Chauhan, Sudhir Kumar; Sætre, Frank Ove; Hagen, Kjersti Thorvaldsen & Yaqub, Sheraz [Vis alle 12 forfattere av denne artikkelen] (2020). CD4+ T cells persist for years in the human small intestine and display a TH1 cytokine profile. Mucosal Immunology. ISSN 1933-0219. 14(2), s. 402–410. doi: 10.1038/s41385-020-0315-5. Fulltekst i vitenarkiv Vis sammendrag

  Studies in mice and humans have shown that CD8+ T cell immunosurveillance in non-lymphoid tissues is dominated by resident populations. Whether CD4+ T cells use the same strategies to survey peripheral tissues is less clear. Here, examining the turnover of CD4+ T cells in transplanted duodenum in humans, we demonstrate that the majority of CD4+ T cells were still donor-derived one year after transplantation. In contrast to memory CD4+ T cells in peripheral blood, intestinal CD4+ TRM cells expressed CD69 and CD161, but only a minor fraction expressed CD103. Functionally, intestinal CD4+ TRM cells were very potent cytokine producers; the vast majority being polyfunctional TH1 cells, whereas a minor fraction produced IL-17. Interestingly, a fraction of intestinal CD4+ T cells produced granzyme-B and perforin after activation. Together, we show that the intestinal CD4+ T-cell compartment is dominated by resident populations that survive for more than 1 year. This finding is of high relevance for the development of oral vaccines and therapies for diseases in the gut.

• Dagenborg, Vegar Johansen; Marshall, Serena Elizabeth; Grzyb, Krzysztof; Fretland, Åsmund Avdem; Lund-Iversen, Marius & Mælandsmo, Gunhild Mari [Vis alle 10 forfattere av denne artikkelen] (2020). Low concordance between T-cell densities in matched primary tumors and liver metastases in microsatellite stable colorectal cancer. Frontiers in Oncology. 11. Fulltekst i vitenarkiv
• Sahakyan, Mushegh; Tholfsen, Tore; Kleive, Dyre; Yaqub, Sheraz; Kazaryan, Airazat M. & Buanes, Trond [Vis alle 9 forfattere av denne artikkelen] (2020). Laparoscopic distal pancreatectomy following prior upper abdominal surgery (pancreatectomy and prior surgery). Journal of Gastrointestinal Surgery. ISSN 1091-255X. s. 1–8. doi: 10.1007/s11605-020-04858-2. Fulltekst i vitenarkiv Vis sammendrag

  Abstract Background and Purpose Previous abdominal surgery can be a risk factor for perioperative complications in patients undergoing laparoscopic procedures. Today, distal pancreatectomy is increasingly performed laparoscopically. This study investigates the consequences of prior upper abdominal surgery (PUAS) for laparoscopic distal pancreatectomy (LDP). Methods Patients who had undergone LDP from April 1997 to January 2020 were included. Based on the history and type of PUAS, these were categorized into three groups: minimally invasive (I), open (II), and no PUAS (III). To reduce possible confounding factors, the groups were matched in 1:2:4 fashion based on age, sex, body mass index (BMI) and American Society of Anesthesiology grade. Results After matching, 30, 60, and 120 patients were included in the minimally invasive, open and no PUAS groups, respectively. No statistically significant differences were found in terms of intraoperative outcomes. Postoperative morbidity, mortality and length of hospital stay were similar. Open PUAS was associated with higher Comprehensive Complication Index (33.7 vs 20.9 vs 26.2, p  = 0.03) and greater proportion of patients with ≥ 2 complications (16.7 vs 0 vs 6.7%, p  = 0.02) compared with minimally invasive and no PUAS. Male sex, overweight (BMI 25–29.9 kg/m 2 ), diagnosis of neuroendocrine neoplasia, and open PUAS were risk factors for severe morbidity in the univariable analysis. Only open PUAS was statistically significant in the multivariable model. Conclusions PUAS does not impair the feasibility and safety of LDP as its perioperative outcomes are largely comparable to those in patients without PUAS. However, open PUAS increases the burden and severity of postoperative complications.

• Brudvik, Kristoffer Watten; Yaqub, Sheraz; Kemsley, E; Coolsen, MME; Dejong, CHC & Wigmore, SJ [Vis alle 7 forfattere av denne artikkelen] (2019). Survey of the attitudes of hepatopancreaticobiliary surgeons in northern Europe to resection of choledohal cysts in asymptomatic Western adults. BJS Open. doi: 10.1002/bjs5.50208. Fulltekst i vitenarkiv
• Casado, Raquel Bartolomé; Landsverk, Ole J. B.; Chauhan, Sudhir Kumar; Richter, Lisa Maria; Phung, Danh & Greiff, Victor [Vis alle 18 forfattere av denne artikkelen] (2019). Resident memory CD8 T cells persist for years in human small intestine. Journal of Experimental Medicine (JEM). ISSN 0022-1007. 216(10), s. 2412–2426. doi: 10.1084/jem.20190414. Fulltekst i vitenarkiv Vis sammendrag

  Resident memory CD8 T (Trm) cells have been shown to provide effective protective responses in the small intestine (SI) in mice. A better understanding of the generation and persistence of SI CD8 Trm cells in humans may have implications for intestinal immune-mediated diseases and vaccine development. Analyzing normal and transplanted human SI, we demonstrated that the majority of SI CD8 T cells were bona fide CD8 Trm cells that survived for &amp;gt;1 yr in the graft. Intraepithelial and lamina propria CD8 Trm cells showed a high clonal overlap and a repertoire dominated by expanded clones, conserved both spatially in the intestine and over time. Functionally, lamina propria CD8 Trm cells were potent cytokine producers, exhibiting a polyfunctional (IFN-γ+ IL-2+ TNF-α+) profile, and efficiently expressed cytotoxic mediators after stimulation. These results suggest that SI CD8 Trm cells could be relevant targets for future oral vaccines and therapeutic strategies for gut disorders.

• Brudvik, Kristoffer Watten; Røsok, Bård Ingvald; naresh, usha; Yaqub, Sheraz; Fretland, Åsmund Avdem & Labori, Knut Jørgen [Vis alle 8 forfattere av denne artikkelen] (2018). Survival after resection of colorectal liver metastases in octogenarians and sexagenarians compared to their respective age-matched national population. Hepatobiliary surgery and nutrition. ISSN 2304-3881. 7(4), s. 234–241. doi: 10.21037/hbsn.2017.09.03. Fulltekst i vitenarkiv
• Fretland, Åsmund Avdem; Dagenborg, Vegar Johansen; Bjørnelv, Gudrun Maria Waaler; Kazaryan, Airazat M.; Kristiansen, Ronny & Fagerland, Morten [Vis alle 17 forfattere av denne artikkelen] (2018). Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial. Annals of Surgery. ISSN 0003-4932. 267(2), s. 199–207. doi: 10.1097/SLA.0000000000002353. Fulltekst i vitenarkiv Vis sammendrag

  Objective: To perform the first randomized controlled trial to compare laparoscopic and open liver resection. Summary Background Data: Laparoscopic liver resection is increasingly used for the surgical treatment of liver tumors.However, high-level evidence to conclude that laparoscopic liver resection is superior to open liver resection is lacking. Methods: Explanatory, assessor-blinded, single center, randomized superiority trial recruiting patients from Oslo University Hospital, Oslo, Norway from February 2012 to January 2016. A total of 280 patients with resectable liver metastases from colorectal cancer were randomly assigned to undergo laparoscopic (n ¼ 133) or open (n ¼ 147) parenchyma-sparing liver resection. The primary outcome was postoperative complications within 30 days (Accordion grade 2 or higher). Secondary outcomes included cost-effectiveness, postoperative hospital stay, blood loss, operation time, and resection margins. Results: The postoperative complication rate was 19% in the laparoscopicsurgery group and 31% in the open-surgery group (12 percentage points difference [95% confidence interval 1.67–21.8; P ¼ 0.021]). The postoperative hospital stay was shorter for laparoscopic surgery (53 vs 96 hours, P < 0.001), whereas there were no differences in blood loss, operation time, and resection margins. Mortality at 90 days did not differ significantly from the laparoscopic group (0 patients) to the open group (1 patient). In a 4-month perspective, the costs were equal, whereas patients in the laparoscopicsurgery group gained 0.011 quality-adjusted life years compared to patients in the open-surgery group (P ¼ 0.001). Conclusions: In patients undergoing parenchyma-sparing liver resection for colorectal metastases, laparoscopic surgery was associated with significantly less postoperative complications compared to open surgery. Laparoscopic resection was cost-effective compared to open resection with a 67% probability. The rate of free resection margins was the same in both groups. Our results support the continued implementation of laparoscopic liver resection. Keywords: colorectal liver metastases, cost and cost analysis, hepatectomy, laparoscopic, laparoscopy, liver resection, minimally invasive surgery, parenchyma-sparing liver surgery, randomized clinical trial, randomized controlled trial

• Richter, Lisa Maria; Landsverk, Ole J. B.; Atlasy, Nader; Bujko, Anna; Yaqub, Sheraz & Horneland, Rune [Vis alle 12 forfattere av denne artikkelen] (2018). Transcriptional profiling reveals monocyte-related macrophages phenotypically resembling DC in human intestine. Mucosal Immunology. ISSN 1933-0219. 11(5), s. 1512–1523. doi: 10.1038/s41385-018-0060-1. Fulltekst i vitenarkiv Vis sammendrag

  The tissue dendritic cell (DC) compartment is heterogeneous, and the ontogeny and functional specialization of human tissue conventional DC (cDC) subsets and their relationship with monocytes is unresolved. Here we identify monocyte-related CSF1R+Flt3- antigen presenting cells (APCs) that constitute about half of the cells classically defined as SIRPα+ DCs in the steady-state human small intestine. CSF1R+Flt3- APCs express calprotectin and very low levels of CD14, are transcriptionally related to monocyte-derived cells, and accumulate during inflammation. CSF1R+Flt3- APCs show typical macrophage characteristics functionally distinct from their Flt3+ cDC counterparts: under steady-state conditions they excel at antigen uptake, have a lower migratory potential, and are inefficient activators of naïve T cells. These results have important implications for the understanding of the ontogenetic and functional heterogeneity within human tissue DCs and their relation to the monocyte lineage.

• Landsverk, Ole J. B.; Snir, Omri; Casado, Raquel Bartolome; Richter, Lisa Maria; Mold, Jeff E. & Réu, Pedro [Vis alle 18 forfattere av denne artikkelen] (2017). Antibody-secreting plasma cells persist for decades in human intestine. Journal of Experimental Medicine (JEM). ISSN 0022-1007. 214(2), s. 309–317. doi: 10.1084/jem.20161590. Fulltekst i vitenarkiv Vis sammendrag

  Plasma cells (PCs) produce antibodies that mediate immunity after infection or vaccination. In contrast to PCs in the bone marrow, PCs in the gut have been considered short lived. In this study, we studied PC dynamics in the human small intestine by cell-turnover analysis in organ transplants and by retrospective cell birth dating measuring carbon-14 in genomic DNA. We identified three distinct PC subsets: a CD19+ PC subset was dynamically exchanged, whereas of two CD19− PC subsets, CD45+ PCs exhibited little and CD45− PCs no replacement and had a median age of 11 and 22 yr, respectively. Accumulation of CD45− PCs during ageing and the presence of rotavirus-specific clones entirely within the CD19− PC subsets support selection and maintenance of protective PCs for life in human intestine.

• Quintana, Daniel; Westlye, Lars Tjelta; Hope, Sigrun; Nærland, Terje; Elvsåshagen, Torbjørn & Dørum, Erlend Solberg [Vis alle 16 forfattere av denne artikkelen] (2017). Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial. Translational Psychiatry. e1136(7), s. 1–9. doi: 10.1038/tp.2017.103. Fulltekst i vitenarkiv
• Bujko, Anna; Atlasy, Nader; Landsverk, Ole J. B.; Richter, Lisa Maria; Yaqub, Sheraz & Horneland, Rune [Vis alle 12 forfattere av denne artikkelen] (2017). Transcriptional and functional profiling defines human small intestinal macrophage subsets. Journal of Experimental Medicine (JEM). ISSN 0022-1007. 215(2), s. 441–458. doi: 10.1084/jem.20170057. Fulltekst i vitenarkiv
• Schultz, Johannes Kurt; Wallon, Conny; Blecic, Liljana; Forsmo, Håvard Mjørud; Folkesson, Joakim & Buchwald, Pamela [Vis alle 10 forfattere av denne artikkelen] (2017). One-year results of the SCANDIV randomized clinical trial of laparoscopic lavage versus primary resection for acute perforated diverticulitis. British Journal of Surgery. ISSN 0007-1323. 104(10), s. 1382–1392. doi: 10.1002/bjs.10567. Fulltekst i vitenarkiv
• Schultz, Johannes Kurt; Yaqub, Sheraz & Øresland, Tom (2016). Management of diverticular disease in scandinavia. Journal of Clinical Gastroenterology. ISSN 0192-0790. 50, s. S50–S52. doi: 10.1097/MCG.0000000000000642. Fulltekst i vitenarkiv

Se alle arbeider i NVA

• Tholfsen, Tore; Lindeman, Robbert-Jan Sjoerd & Yaqub, Sheraz (2026). Metastase i navlen. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 146(5). doi: 10.4045/tidsskr.25.0661. Fulltekst i vitenarkiv
• Hansen, Ingrid Schrøder; Hårvig, Karina Roheim; Brudvik, Kristoffer Watten; Røsok, Bård Ingvald; Bjørk, Ida Torunn & Østergaard, Daniel [Vis alle 15 forfattere av denne artikkelen] (2025). A Randomized Controlled Trial of Resection Versus Thermal Ablation of Colorectal Cancer Liver Metastases (New Comet): Study Protocol. doi: 10.1245/s10434-025-17984-5. Fulltekst i vitenarkiv Vis sammendrag

  Background. The use of thermal ablation of liver tumors is rapidly increasing. This is despite a lack of high-level evidence of the oncologic efficacy of ablation. Ablation is most often used in cases where resection is not possible, but as the technique has improved it is increasingly used as a substitute for resection. Patients and Methods. New Comet is an international multicenter randomized controlled double-blinded, non inferiority trial comparing thermal ablation to resection of colorectal liver metastases. It will include 230 patients with colorectal liver metastases (up to 5 lesions, tumor size up to 3 cm) where thermal ablation and resection both are considered suitable treatment options for all lesions. The patients are randomized to either resection or ablation, and all lesions in each patient are treated with the same modaliity. Complete ablation will be verified with intraoperative computed tomography and ablation confirmation software. Conclusions. The primary endpoint is local tumor recurrence at 12 months. Secondary endpoints include overall survival, disease-free survival, time to surgical failure, health-related quality of life, complications, and cost-effectiveness (trial registration no.: NCT05129787).

• Yaqub, Sheraz & Tasken, Kjetil (2025). Adjuvant Aspirin Fails in Phase 3 Trial of Patients With Colorectal Cancer Liver Metastases. [Internet]. Oncology News Central. doi: https:/www.oncologynewscentral.com/colorectal-cancer/adjuvant-aspirin-fails-in-phase-3-trial-of-patients-with-colorectal-cancer-liver-metasases. Fulltekst i vitenarkiv
• Yaqub, Sheraz & Tasken, Kjetil (2025). Studie med KLINBEFORSK-finansiering presentert ved ASCO. [Internet]. Helse Sør-øst. doi: https:/www.helse-sorost.no/klinbeforsk/asac-studien-asco/. Fulltekst i vitenarkiv
• Yaqub, Sheraz & Tasken, Kjetil (2025). Aspirin beskytter ikke mot tilbakefall for tarmkreftpasienter med spredning til lever. [Internet]. Oslo universitetssykehus. doi: https:/www.oslo-universitetssykehus.no/om-oss/nyheter/aspirin-beskytter-ikke-mot-tilbakefall-for-tarmkreftpasienter-med-spredning-til-lever/. Fulltekst i vitenarkiv
• Isachsen, Henriette Bertheussen; Yaqub, Sheraz & Tasken, Kjetil (2025). Vi kan ikke anbefale denne pasientgruppen å begynne med aspirin. [Journal]. Dagens medisin. doi: https:/www.dagensmedisin.no/asco-2025-kirurgi-kreft/norsk-kirurg-pa-asco-vi-kan-ikke-anbefale-denne-pasientgruppen-a-begynne-med-aspirin/688581. Fulltekst i vitenarkiv
• Kjeseth, Trond; Line, Pål Dag; Khan, Ammar; Solheim, Jon Magnus Aarstrand; Björk, Ida Gabriella & Sundal, Jon [Vis alle 8 forfattere av denne artikkelen] (2024). Ex-situ liver resection for complex Echinococcus multilocularis infection: a case report. Journal of Surgical Case Reports (JSCR). 2024(6). doi: 10.1093/jscr/rjae410. Fulltekst i vitenarkiv
• Yakub, Sheraz; Edwin, Bjørn von Gohren; Hammoud, Zane; Herrera-Almario, Gabriel; Jabir, Buthaina & Lassen, Kristoffer [Vis alle 23 forfattere av denne artikkelen] (2024). Gaza War: Too many citizens being killed. British Journal of Surgery. ISSN 0007-1323. 111(4). doi: 10.1093/bjs/znae094. Fulltekst i vitenarkiv
• Siriwardena, Ajith K.; Serrablo, Alejandro; Fretland, Åsmund Avdem; Wigmore, Stephen J.; Ramia-Angel, Jose M. & Malik, Hassan Z. [Vis alle 95 forfattere av denne artikkelen] (2023). The multi-societal European consensus on the terminology, diagnosis and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE. HPB. ISSN 1365-182X. 25(9), s. 985–999. doi: 10.1016/j.hpb.2023.05.360. Fulltekst i vitenarkiv
• Yakub, Sheraz; Sparrelid, Ernesto; Sampaio-Neto, José; Lassen, Kristoffer & Wigmore, Stephen J (2023). Israel and Gaza: the killing of civilians must stop. The Lancet. ISSN 0140-6736. 402(10417), s. 2069–2070. doi: 10.1016/S0140-6736(23)02517-5. Fulltekst i vitenarkiv
• Yakub, Sheraz; Bjørk, Ida; Sugulle, Meryam & Folseraas, Trine (2023). Biopsy helpful in diagnosing a liver mass in pregnancy: focal nodular hyperplasia. The Lancet. ISSN 0140-6736. doi: 10.1016/S0140-6736(23)01606-9. Fulltekst i vitenarkiv
• Mala, Tom; Yakub, Sheraz & Saeed, Usman (2023). Redusert kreftrisiko etter fedmekirurgi. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 143(13). doi: 10.4045/tidsskr.23.0501. Fulltekst i vitenarkiv
• Yaqub, Sheraz (2022). Comment on: Synchronous resection of primary colorectal cancer with liver metastases: Two birds with one stone? British Journal of Surgery. ISSN 0007-1323. 109:e101(9), s. e101–e101. doi: 10.1093/bjs/znac144. Fulltekst i vitenarkiv
• Alshbib, Ayham; Grzyb, Krzysztof; Syversveen, Trygve; Reims, Henrik Mikael; Lassen, Kristoffer & Yaqub, Sheraz (2022). Biliary Adenofibroma: A Rare Liver Tumor with Transition to Invasive Carcinoma. Case Reports in Surgery. ISSN 2090-6919. doi: 10.1155/2022/5280884. Fulltekst i vitenarkiv Vis sammendrag

  Biliary adenofibroma is a rare benign liver tumor with potential for malignant transition. It has a bile duct origin characterized by a complex tubulocystic biliary epithelium with fibrous stroma. MRI features may suggest this uncommon entity, and histological findings can be diagnostic. We report a case of biliary adenofibroma with transformation to an intrahepatic cholangiocarcinoma.

• Dueland, Svein; Yaqub, Sheraz & Line, Pål Dag (2022). No Strong Evidence on Liver Transplant for Colorectal Cancer Liver Metastasis Over Portal Vein Embolization Associated With Liver Resection-Reply. JAMA Surgery. ISSN 2168-6254. doi: 10.1001/jamasurg.2021.5127. Fulltekst i vitenarkiv
• Dueland, Svein; Yaqub, Sheraz & Line, Pål Dag (2021). No Strong Evidence on Liver Transplant for Colorectal Cancer Liver Metastasis over Portal Vein Embolization Associated with Liver Resection-Reply. JAMA Surgery. ISSN 2168-6254. doi: 10.1001/jamasurg.2021.5127. Fulltekst i vitenarkiv
• Kazaryan, Airazat M.; Edwin, Bjørn; Darzi, Ara; Sahakyan, Mushegh; Yaqub, Sheraz & Gayet, Brice (2021). Constructive criticism or distortion of the humanitarian narrative? – Authors' reply. The Lancet Global Health. ISSN 2572-116X. 9(3), s. E255–E255. doi: 10.1016/S2214-109X(20)30553-2. Fulltekst i vitenarkiv
• Kazaryan, Airazat; Edwin, Bjørn von Gohren; Darzi, Ara; Tamamyan, Gevorg; Sahakyan, Mushegh & Aghayan, Davit [Vis alle 9 forfattere av denne artikkelen] (2021). War in the time of COVID-19: humanitarian catastrophe in Nagorno-Karabakh and Armenia. The Lancet Global Health. ISSN 2572-116X. doi: 10.1016/S2214-109X(20)30510-6. Fulltekst i vitenarkiv
• Aghayan, Davit; Dagenborg, Vegar Johansen; Grzyb, Krzysztof; Fretland, Åsmund Avdem; Kazaryan, Airazat & Yaqub, Sheraz [Vis alle 8 forfattere av denne artikkelen] (2021). Histopathologic Growth Patterns of Colorectal Liver Metastases for Predicting Survival after Liver Resection: Data from the OSLO-COMET RCT. HPB. ISSN 1365-182X. doi: 10.1016/j.hpb.2020.11.040. Fulltekst i vitenarkiv
• Aghayan, Davit; Fretland, Åsmund Avdem; Røsok, Bård Ingvald; Yaqub, Sheraz & Edwin, Bjørn von Gohren (2021). Laparoscopic parenchyma-sparing liver resection for large colorectal cancer metastases. HPB. ISSN 1365-182X. doi: 10.1016/j.hpb.2021.06.279. Fulltekst i vitenarkiv
• Fosheim, Ingrid Knutsdotter; Hårvig, Karina Roheim; Heldal, Kristian; Mariathasan, Anthony Burton; Lundesgaard, Kristoffer & BENTERUD, BJØRN PETTER [Vis alle 9 forfattere av denne artikkelen] (2021). En ung kvinne som ikke våknet etter omfattende operasjon. Tidsskrift for Den norske legeforening (Tidsskriftet). ISSN 0029-2001. 141(15), s. 1–8. doi: 10.4045/tidsskr.21.0184. Fulltekst i vitenarkiv
• Holmberg, Marcus; Koppatz, Hanna; Jansson, Anders; Hillingsø, Jens Georg; Larsen, Peter Noergaard & Lassen, Kristoffer [Vis alle 9 forfattere av denne artikkelen] (2021). Secondary effects of the COVID-19 pandemic on surgical management of hepatopancreatobiliary malignancies in the Nordic capitals. British Journal of Surgery. ISSN 0007-1323. 109(1). doi: 10.1093/bjs/znab405. Fulltekst i vitenarkiv
• Bains, Simer Jit; Mahic, Milada; Myklebust, Tor Åge; Småstuen, Milada C; Yaqub, Sheraz & Dørum, Liv Marit [Vis alle 10 forfattere av denne artikkelen] (2017). Reply to M. Løberg et al. Journal of Clinical Oncology. ISSN 0732-183X. 35(5), s. 569–570. doi: 10.1200/JCO.2016.70.8263. Fulltekst i vitenarkiv
• Bains, Simer Jit; Mahic, Milada; Myklebust, Tor Åge; Småstuen, Milada C; Yaqub, Sheraz & Dørum, Liv Marit [Vis alle 10 forfattere av denne artikkelen] (2017). Correspondence: Reply to M. Løberg et al. Aspirin, colorectal cancer and cause of Death - a complex landscape. Journal of Clinical Oncology. ISSN 0732-183X. 35(5), s. 569–571. doi: 10.1200/JCO.2016.70.8263. Fulltekst i vitenarkiv

Se alle arbeider i NVA